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Cancer is the 2nd most common cause of death in our society and is 
associated with high morbidity and costs. The word ‘cancer’ amalgamates the 
complex interplay between cells which have acquired genetic alterations 
leading to uncontrolled proliferation, i.e. the malignant cells, and genetically 
‘normal’ host cells, i.e. stromal cells, vascular cells and inflammatory cells 
which all acquire modified biological phenotypes in the presence of malignant 
cells. This community of cells and their secreted proteins defines the tumour 
microenvironment. Stromal cells in the tumour microenvironment display 
characteristic biological changes which promote cancer growth. Little is 
known on the underlying regulatory mechanisms defining this phenotype. 
Epigenetics describes inheritable changes not encoded by the nucleic acid 
sequence. Epigenetic regulation has been described to occur in stromal cells 
in the tumour microenvironment, but little is known about its role on 
myofibroblasts.  
In this work I describe how oesophageal cancer derived stromal cells, i.e. 
cancer associated myofibroblasts (CAMs) accelerate tumour growth in vivo. I 
observed that CAMs not only affect the local tumour microenvironment but 
might also accelerate tumour growth at a distant site. I also show how 
myofibroblasts play an important role in early tumour niche formation in 
xenograft models and describe their disappearance and replacement by 
murine stromal cells during tumour progression. 
Oesophageal CAMs were shown to be epigenetically distinct from matched 
adjacent tissue myofibroblasts (ATMs). They exhibited a global DNA hypo-
methylation compared to ATMs. We identified distinct DNA methylation 
signatures between oesophageal cancer CAMs and ATMs with the use of the 
Illumina 450k bead chip methylation array. The methylation array data 
showed altered methylation signatures of genes implicated Wnt/β-catenin 
signalling pathway. The transcription factor paired like homeodomain (PITX) 2 
and the regulatory protein secreted frizzled like protein (SFRP) 2 both showed 
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altered methylation signatures and expression patterns between oesophageal 
cancer CAMs and ATMs. I found that upregulation of SFRP2 in 
myofibroblasts induces angiogenesis and I hypothesise that epigenetic 
modification regulates myofibroblasts-derived SFRP2 expression which may 
play an important role in tumour neovascularisation. Based on these findings I 
conclude that ATMs and CAMs are epigenetically distinct and altered protein 
expression is at least partially regulated by altered DNA methylation.  
This work also presents a model for epigenetic modification of tumour stroma 
cells: exposure of myofibroblasts to the DNA methyl transferase inhibitor 
5’Aza-3’deoxy cytosine (DAC) lead to a mild decrease of global DNA 
methylation and induced persistent biological changes in myofibroblasts. 
These epigenetically modified myofibroblasts induced an accelerated 
xenograft growth when injected together with oesophageal cancer cells. 
Based on these experiments I conclude that DAC epigenetically modifies 
myofibroblasts which induces an activation of normally silenced genes 





The work described in this thesis addresses the hypothesis that oesophageal cancer 
associated myofibroblasts are epigenetically distinct from tumour adjacent tissue 
myofibroblasts and that some biological differences between the two are 





4.1 History of Cancer in Medicine(1) 
Tumours have captured the attention of scientists and doctors since ancient 
times. Medical scripts originating from the five ancient high cultures (China, 
India, Persia, Babylonia and Egypt) contain descriptions and treatment plans 
for cancer. The first known historic documentation of tumours comes from 
ancient Egypt and originated from ancient papyri transcripts originally written 
around 2650 BC, the time of Imhotep who was a high priest, doctor and 
architect of the first pyramid and vizier to King Djoser.  A transcript dated to 
1950-1550 BC is the so called Edwin Smith, Ebers and Kahoun medical 
papyri, named after its 19th century discoverers (2). Also in the ancient 
Sanskrit epic Ramayana originating from the period around 1200-1000 BC 
and written in 400-200 BC there are descriptions of cancers and their 
treatment. The first documentation and explanation for the origin of cancers is 
attributed to the Greek doctor Hippocrates born on the isle of Kos 460 BC. 
Hippocrates revolutionised medicine, abolishing mystic explanations, and 
based his ideas on those of the Greek philosopher Empedocles who lived in 
the 5th century BC. Hippocrates thought that the body consisted of the four 
elements, i.e. earth, air, fire and water. He hypothesised that diseases are the 
result of a disequilibrium of the four elements of blood, phlegm, black bile and 
yellow bile. He postulated that cancer was the result of too much of black bile. 
Hippocrates introduced the term ‘carcinos’ which means ‘crab’ in Greek 
believed to be related to the prominent static blood vessels that surround 
tumours. Later the Roman aristocrat Aurelius Cornelius Celsus (ca 30 BC – 
AD 38) documented tumours in his books entitled ‘de medicina’. Another 
important exponent of Roman medical history was undoubtedly Claudius 
Galenus, a surgeon who was born in AD 130. Galenus took over Hippocrates’ 
ideas and further developed them. He believed that the deposition of black 
bile in certain parts of the body led to the development of tumours which he 
called ‘cancer’. During medieval times medical progress stalled in the West, 
whereas it thrived in the Chinese empire. In the Chinese Tang dynasty (618-
907) Sun Simiao (581-627) divided tumours into bony, fatty, stony and 
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suppurating tumours as well as tumours of muscles and blood vessels. In 
Europe, only with the beginning of the Renaissance, the dogma of black bile 
as the origin for malignancies was slowly rejected. The Parisian surgeon 
Henri François le Duran (1685-1770) published a theory stating that cancer is 
a local complaint, at least in its early stages, based on observations on post 
mortems. He also described the dissemination of breast cancer via the lymph 
ducts to the lymph nodes in various parts of the body and stressed the 
likelihood of relapses (3). Major advances in the understanding of cancer 
were gained through studies of pathological anatomy, for example as 
expounded by Giovanni Battista Morgagni (1682-1771) who was professor of 
theoretical medicine and anatomy at the University of Padua. Morgagni 
published the monumental work ‘De sedibus et causis morborum et 
anatomen indagatis’ (About the location and causes of disease) in five books 
(4). Further advances on the understanding of cancer were closely related to 
the invention of microscopy by the Dutch spectacle-maker Hans Janssen 
from Middelburth and his son Zacharias (ca. 1580-1638) which allowed the 
study of disease at cellular level. This lead to the development of the cell 
theory in 1838 by the German physiologist Theodor Schwann (1810-1882) 
who together with the botanist Matthias Jakob Schleiden (1804-1881) 
declared that all plants and animals were made up of cells and cellular 
products. Everard Home (1756-1832) was the first to study cancer with a 
microscope, and described his findings in his book ‘A short tract on the 
formation of tumours, and the peculiarities that are met within the structure of 
those who have become cancerous, with their mode of treatment’ in 1830 (5). 
This was followed by the publication of the German pathologist Johannes 
Müller (1801-1858) who described in this work ‘Ueber den feinen Bau und die 
Formen der krankhaften Geschwülste’ (On the delicate built and the different 
forms of morbid tumours) published in 1838 (6). He distinguished different 
types of tumours on the basis of their microscopic structure, supporting the 
macroscopic descriptions by René Théophile Hyacinthe Laënnec (1781-1826) 
(7).  It was the Danish pathologist Adolph Hannover who published in 1843 
his book ‘Das Epithelioma’ (the epithelioma), a description of cancer cells and 
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their normal counterparts (8). The basic characteristics of malignant tumours 
were then defined with the publication of ‘die Cellularpathologie’ (cellular 
pathology) (9) published by the founder of histopathology and former 
Professor of Anatomy at the Charitée in Berlin, Rudolf Ludwig Karl Virchow 
(1821-1901). He established the medical dogma ‘omnis cellula e cellula’ 
(every cell derives from another cell) and also that each tumour originates 
from the cells of the organ in which it develops. Johannes Müller and Rudolf 
Virchow concluded that a cancer was made up from two components the 
malignant parenchyma and the benign stroma that consists of fibrous 
connective tissue and blood vessels. Langenbeck postulated that every single 
cancer cell must be regarded as an organism, alive and capable of 
development. It was Stephen Paget who in 1889 described the relation 
between primary tumour and site of metastasis in his ‘seed and soil’ theory 
based on a post mortem study of breast cancer patients(10).  
Further advances in understanding malignant tumours went in parallel with 
technological progress. Probably, the first experimental approaches with the 
intention to treat cancer go back to the mid-19th century when Joseph Leidy 
grafted fragments of breast tumours into frogs. He observed that capillaries 
from the frog penetrated the transplanted tissue. Arthur Nathan Hanau, a 
German-Swiss pathologist successfully induced peritoneal metastasis after 
transplanting solid carcinoma fragments between rats in 1888 (11). 
Techniques which allowed the culture of cells outside the body were 
developed in the early 20th century initially by MT Burrows and Alexis Carrel. 
The basis of modern molecular techniques was set with the discovery of 
deoxyribose nucleic acid (DNA) by Friedrich Miescher in Tübingen in 1869 
even though its significance remained unclear until the genetic code was 
deciphered by James Watson and Francis Crick in 1953 (12) on the basis of 
x-ray crystallography by Rosalind Franklin.  
The idea of a genetic basis of cancer emerged with the publication of 
chormosomal aberation by Theodor Boveri (1862-1915) in 1914 where he 
stated that mutations in somatic cells lead to uncontrolled cell proliferation 
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(13). Its involvement in cell fate became evident with the realisation that 
human cells consists of 46 chromosomes in 1956 by Joe Hin Tjio and Albert 
Levan (14). This was followed by the description of chromosomal aberrations 
and a description of the first malignancy-related chromosomal aberration in 
1960 by the two pathologists Peter Carey Nowell and David Hungerford in 
Philadelphia (15). They observed the translocation between chromosomes 9 
and 22 t(9;22)(q34;q11), the so called Philadelphia chromosome, which leads 
to constitutive activation of the Abl tyrosine kinase (16, 17). Techniques 
allowing the identification of DNA by Southern blotting in 1975(18), of 
ribonucleic acid (RNA) by northern blotting in 1977 (19) and proteins by 
western blotting (20) took the field of anti-cancer research further.  
The characterisation of cells using antibodies first emerged in the 1930s, but 
it was only in 1941 that Albert Coons described the first fluorescent 
immunohistological studies which he subsequently developed further (21). 
The linking of antibodies to enzymatic visualisation reactions (immune 
peroxidase reactions (22) and alkaline phosphatase (23)) allowed their use in 
routine clinical diagnostic methods.  
Knowledge gained on DNA manipulation by cloning into vectors and the 
establishment of the polymerase chain reaction (PCR) (24-26) and dideoxy 
sequencing as first described by Frederick Sanger in 1977 (27) were further 
technical milestones which led in the end to the sequencing of the complete 
first human chromosome in 2006 (28). Visualisation of individual genes by 
fluorescence in situ hybridisation was first published in 1982 (29) and has 
since then become a standard procedure in routine tumour diagnosis with 
prognostic and predictive value. Sequencing based technologies have now 
become part of routine tumour diagnostics not only of prognostic but more 
importantly of predictive value. The field continues to develop rapidly in 
parallel with technology (30, 31). Tumour monitoring based on circulating 
tumour cells (32) and circulating tumour DNA and miRNA in micro vesicles 
(33, 34) are the latest techniques offered to cancer patients. 
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Manipulation of cells at the protein level using antibodies became possible 
after the development of monoclonal antibodies in the late 1970s (35). 
Manipulation of transcription by RNA interference was discovered by Andrew 
Fire and Craig Mello in 1998 (36, 37) and its latest tool CRISPR/Cas9 (38).  
4.2 Anticancer therapy 
Treatment of cancer was restricted to surgery until 1896 when the first 
successful anti-cancer radiotherapy cases were described by A. Voigt and 
later also by Emil Grubbe (39). Leukaemias were treated with the so called 
Fowler’s solution (potassium arsenic) by the Stafford doctor Fowler in 1786. 
The word chemotherapy is attributed to Paul Ehrlich’s (1854-1915) treatment 
of infectious disease in rodents. Ehrlich’s idea was taken to the next level by 
George Clowes (1877-1958) who started to test chemical compounds on 
inbred rodents in order to screen for potential anticancer drugs. The American 
pathologists E. B. and Helen D. Krumbhaar observed in post mortem studies 
of soldiers who had been exposed to mustard gas in World War I an atrophy 
of the lymphatic and testicular tissue as well as damage to the bone marrow 
(40). The significance of this remained unclear until the discovery of nitrogen 
mustard cytostatics and the first application of such in 1942 on a patient with 
radiation resistant non-Hodgkin lymphoma by Albert Gilman (41). In 1948 
Sidney Farber published the first successful chemotherapy using folic acid 
analogues in acute lymphatic leukaemia (42). Various toxic chemical 
compounds have followed since then.   
The idea of a hormonal dimension to cancer control originates in empirical 
case studies described by George Thomas Beatson (1848-1933) in 1896(43). 
Beatson performed bilateral oophorectomies in advanced breast cancer 
patients and observed remarkable remission of disease. The underlying 
mechanism of hormone deprivation became a corner stone in ablative 
hormone therapy in breast cancer first described by W. M. Biden in 1943 and 
published as a clinical trial by Alexander Haddow (1907-1976) (44).  
In the late 1990s the field of anticancer therapy was revolutionised with the 
introduction of the first monoclonal antibody therapy targeting the BCR-ABL 
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fusion protein (45-47). Numerous other antibodies have followed and so 
called small molecule drugs interfering with single proteins have followed 
since then. 
In the last decade agents targeting epigenetic changes have been 
successfully tested as anti cancer therapies. Agents which target DNA 
methylation (48, 49) were developed and as an example 5’Aza-3’deoxy 
cytosine has been approved for the treatment of myelodysplastic syndrome in 
2006. Epigenetic inhibitors, known as EpiDrugs have recently been 
introduced for anti-tumour therapy (50).  
4.3 Morphology of malignant tumours 
Recognising the abnormal requires deep knowledge of the normal. 
Understanding of normal anatomy, histology and molecular characteristics 
and their physiological state has therefore been a prerequisite for the 
differentiation between malignant and benign. Already in ancient Egyptian, 
Greek and Roman times studies of anatomy were documented, but progress 
was slow. Only in the Renaissance the study of the human anatomy was 
launched by pioneers such as Leonardo Da Vinci and Andreas Vesalius. 
Vesalius is regarded as the father of modern anatomy as a consequence of 
his work ‘De humani corporis fabrica’ (On the building of the human body) 
published in 1543 (51). The first macroscopic description of tumours ‘The 
Morbid Anatomy of Some of the Most Important Parts of the Human Body’, 
was published by Matthew Baillie in 1793 (52). As mentioned above technical 
developments such as the invention of the microscope led to further 
understanding of cancers and up to date histological characteristics are still 
the main criteria to classify cancers. They are revised on a regular basis by 
the World Health Organisation (WHO) in their series of WHO classification of 
Tumours, published by the International Agency for Research on Cancer 
(IARC).  
4.4 The concept of neoplasia 
Neoplasias can be regarded as de-novo proliferative diseases and are 
subdivided based on the behaviour of tumours as benign, semi-malignant and 
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malignant. The latter are defined by their malignant growth pattern and their 
ability to metastasise. Malignant tumours can be sub-classified as epithelial-
derived neoplasias, i.e. carcinomas; proliferative disease of the hematopoietic 
system, i.e. lymphomas and leukaemias; tumours of soft tissues and 
articulation, i.e. sarcomas and of mesothelial origin, i.e. mesotheliomas. 
Tumours of the central nervous system and the meninges are classified as 
gliomas and tumours of the meninges. Malignant tumours are classified, 
staged and graded according to the WHO/IARC guidelines and TNM 
classification. These days many malignant tumours are defined based on 
their molecular/genetic alterations (for example loss of heterozygocity, gene 
rearrangements, gene copy number alterations, mutations and many more) 
with not only prognostic but also predictive relevance. The mechanism 
leading to malignant tumours (i.e. tumour or carcinogenesis) can be regarded 
as an accumulation of genetic errors in a normal cell leading to an 
uncontrolled proliferation, change of behaviour in the tissue and migration 
within the body. Douglas Hanahan and Robert Weinberg have summarised 
cancer in their two milestone reviews ‘the hallmark of cancer’ (53, 54). They 
describe cancers as being able to thrive independently of proliferative 
signalling and to evade growth suppression. Cancer cells possess the 
enablement of replicative immortality, induction of angiogenesis, resistance to 
cell death and lastly the ability to invade and metastasise. Cancer is the 2nd 
most common cause of death in industrialised countries (around 20-25 % in 
the UK (55)).  Big current questions are how to overcome the drive of 
malignant cells to escape current therapies. One small part of this main goal 
to control of cancer is the understanding of the tumour stroma. Since Paget’s 
‘seed and soil’ paradigm has been established (10), the tumour stroma has 
been known to play a pivotal role in metastasis. We know now that the tumour 
stroma in some cases directly interacts with malignant cells and plays an 
important role in progression.  
4.5 Tumour microenvironment 
The tumour microenvironment is a complex mixture of cancer cells and non-
malignant cells of the host tissue (i.e. inflammatory, stromal and vascular 
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cells). These cells interact at different levels, supporting growth advantage, 
invasion, intravasation and metastasis of cancer cells, but also homing of 
inflammatory cells, mesenchymal stem cells, stomal cells and 
neovascularisation (for review see Hanahan & Weinberg (53, 54)).  
4.6 Cancer cells 
Cancer cells are the consequence of many genetic and epigenetic 
aberrations leading to loss of tumour suppressor genes and activation of 
oncogenes which in turn leads to independent growth with the ability to 
infiltrate and destroy the adjacent tissue and to metastasise.  
4.7 Myofibroblasts 
Myofibroblasts can be regarded as a subtype of stromal fibroblasts which 
show myogenic differentiation (56, 57). In various organs myofibroblasts 
evolve from mesoderm during embryogenesis. In the tumour 
microenvironment however, many myofibroblasts are recruited from the local 
environment (58). For example, cancer cells secrete a variety of growth 
factors such as transforming growth factor (TGF) β (59, 60) and platelet-
derived growth factor (PDGF) (61, 62) which have been shown to induce 
CAMs. In the case of squamous cell carcinoma in the oral cavity, the cancer 
cells induce an ‘activated’ myofibroblasts phenotype via TGFβ-1 signalling 
(63). Upper gastrointestinal cancer cells can increase cancer associated 
stromal cell proliferation which in turn promotes epithelial to mesenchymal 
transition (EMT) in cancer cells (64).  
In addition, already over two decades ago a subtype of circulating cells in 
peripheral blood was identified as being adherent on plastic and were showed 
to exhibit a mesenchymal expression signature (vimentin, collagen and 
CD34): they were called fibrocytes (65). Fibrocytes were described to have 
the propensity to home towards scar tissue. Similarly a portion of 
myofibroblasts within the tumour bulk may derive from primary local cells 
such as resident mesenchymal stem cells (MSC) or can originate from bone 
marrow-MSCs (66, 67). Fibrocytes harvested from peripheral blood have 
been shown to accelerate gastric MKN45 tumour growth in vivo (68). 
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Myofibroblasts have also been described to originate from malignant tumour 
cells which have undergone EMT (69). 
A characteristic feature of myofibroblasts in conventional light microscopy is 
the so-called desmoplastic stroma reaction which features activated 
myofibroblastic cells surrounding cancer cells. Myofibroblasts can present 
under a similar picture in granulation tissue and wound healing. 
Myofibroblasts are characterised by their stromal appearance and their 
expression of the stromal cell markers αSMA, vimentin, fibroblast activating 
protein (FAP) (70) and the lack of epithelial characterisation markers such as 
cytokeratins 8 and 20 and E-cadherin (71). A growing body of evidence 
indicates that there is considerable heterogeneity in myofibroblasts 
populations (71). All cells designated as myofibroblasts in this thesis were 
previously characterised by their lack of cytokeratin and E-cadherin 
expression and their immunoreactivity towards αSMA and vimentin.  
This thesis describes work with myofibroblasts derived from organs of 
tumour-free patients, i.e. normal tissue myofibroblasts (NTM) as well as 
myofibroblasts derived from patients with cancer. In the latter we differentiate 
between myofibroblasts derived from the tumour bulk, i.e. cancer associated 
myofibroblasts (CAMs) and myofibroblasts derived from tumour adjacent, 
macroscopically tumour free tissue, i.e. adjacent tissue myofibroblasts 




Figure 1: Abstracted figure of our conception of myofibroblasts.  
 
It has been shown that CAMs differ from ATMs in various dimensions. They 
display a distinct morphological difference with increased nuclear size, altered 
chromatin structure and increase of rough endoplasmic reticulum (74), by 
their secretory and contractile phenotype together with increased expression 
of PAI-1(75-77), αSMA(78, 79), laminin and fibronectin (80) and differential 
secretion of metalloproteinases (81). Also at a transcriptional level, cancer 
associated stromal cells show distinct signatures in lung cancer (82), breast 
cancer (83), oesophageal cancer (84) and colorectal cancer (85). For review 
see (71).  
Stromal cells show tissue specific lineage differentiation which also applies to 
gastrointestinal fibroblasts as described by Higuchi and his colleagues (86). 
Fibroblasts have distinct transcriptomes, which allows segregation between 
gastrointestinal and fibroblasts from other provenience. Furthermore this 
group described gene expression signatures differentiating between 
submucosal and subserosal origin and a differential homeotic gene 
expression pattern along the intestinal axis (oesophagus, stomach, 
duodenum, ileum and colon). There are also distinct miRNA signatures 
described in gastrointestinal myofibroblasts (87). 
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4.7.1 Role of stromal cells on tumour growth 
Cancer stromal cells secrete a broad spectrum of cytokines and chemokines. 
CAMs have been shown to sustain proliferative activity by secretion of a 
variety of growth factors (insulin like growth factor (IGF) 2, stroma cell derived 
factor (SDF) 1, hepatocyte growth factor 1) which directly stimulate cancer 
cell proliferation (88) but have also been described to be involved in the 
initiation of aberrant proliferation in stem cells or tumour initiation cells (89). 
Conditioned medium (CM) from pancreatic stellate cells which are regarded 
as a source of myofibroblastic stroma have been shown to increase tumour 
cell proliferation with an activation of the ERK signalling cascade and to 
interfere with drug induced cell death in pancreatic cancer cell lines (90). 
Oesophageal cancer associated fibroblasts (CAFs) secrete periostin which 
leads to a PI3kinase-AKT pathway activation in oesophageal cancer cells. 
Periostin at the cellular interface between CAF and cancer cells is associated 
with more aggressive tumour behaviour (84).  
CAMs also indirectly stimulate tumour growth through their effect on 
angiogenesis by the release of vascular endothelial growth factor (VEGF), 
fibrobast growth factor (FGF) 2 and osteopontin which increases vascular 
density in the tumour through their angiogenetic stimuli (91-93).  
Furthermore CAMs play an important role in tissue remodelling where they 
exert their effect through the secretion of matrix metalloproteinases (MMPs), 
tissue inhibitors of metalloproteinases (TIMPs) and a variety of matrix 
proteins and signalling peptides (81, 94) which lead to the characteristic 
stiffness of tumour tissue (68). Work published by the group has shown that 
myofibroblasts in the tumour microenvironment play an important role in the 
recruitment of mesenchymal stromal cells to the tumour site (95). MSC can 
then differentiate themselves into CAMs (96). 
Evidence of reciprocal stimuli between cancer cells and stromal cells was 
demonstrated by Terai and his colleagues: when gastric MKN45 cancer cells 
were cultured together with bone marrow derived fibrocytes (65) the cancer 
cells showed increased expression of SDF-1 and E-cadherin whereas the 
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stromal cells showed an increase in their expression of collagen type I and 
αSMA (68). The group further observed an accelerated tumour growth of 
xenografts when primary fibrocytes were co-injected together with the cancer 
cells and an increased αSMA positive stromal cell component in these 
tumours. This stands in parallel with findings described and data produced in 
our lab where injection of CAM together with different cancer cells accelerate 
tumour cell growth (97, 98). 
4.8 Epigenetics 
Epigenetic changes can be described as gene transcript-affecting 
modifications which are not defined by the four base pair code of the DNA. 
The field of epigenetic modification has been growing rapidly since the 
beginning of the 21st century and currently altered DNA methylation (99), 
histone modification (100), nuclear structure arrangement (101), RNA 
interference (102), post translational modification (103) and prions (104) are 
regarded as epigenetic changes. Epigenetic changes have major impact on 
non-expansional and proliferative (cancerous) human diseases and are 
related to aberrant gene expression. A particular feature of cancer cells is the 
loss of global DNA methylation which has been associated with chromosomal 
instability, activation of transposable elements and loss of genomic imprinting 
which all contribute to an increase in genomic entropy resulting in aberrant 
gene expression (105).  
DNA methylation in genomic eukaryotic DNA occurs predominantly in 
repetitive regions, including satellite DNA, short interspersed transposable 
elements (SINE) and long interspersed transposable elements (LINE). DNA 
methylation of LINE elements can therefore be assessed as a marker for 
global DNA methylation (106).  
Aberrant DNA methylation as a surrogate for epigenetic modification in 
malignant cells is regarded as a hallmark of malignancy (54, 107). Relatively 
little is known of such alterations in cancer associated non-neoplastic stromal 
cells (85, 108), even though the latter are known to be directly involved in 
tumour progression (73, 109). Treatment of pancreatic cancer myofibroblasts 
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with the demethylating agents azacyitidine (AZT) and 5-aza-2'-deoxycytidine 
(decitabine; DAC) leads to an induction of epigenetically silenced genes (110). 
DNA methyl transferases (DNMTs) play a key role in promoter 
hypermethylation and concomitant loss of gene expression (for review see 
(111)). 
DNA promoter methylation is a major definer of transcriptional regulation. 
DNA methylation patterns are passed onto daughter cells in cell division, 
mainly through DNMT1. The inhibition of the DNMT1 by DAC is directly 
associated with increased gene transcription. Downregulation of tumour 
suppressor genes by promoter hypermethylation is a commonly observed 
epigenetic modification in cancers. Accordingly, in oncology, drugs interfering 
with the epigenetic regulation are in use for selected malignancies (112). 
The two demethylating agents AZT and DAC are established for treatment of 
solid and hematopoietic neoplasias respectively. DAC is an analogue of 
cytosine that when incorporated into DNA irreversibly binds DNMT1 and 3B 
(49) and leads to a lack of methylation in the daughter strand during DNA 




Figure 2: Mode of action of DAC. Modified form EA Griffiths and SD Gore, 
Advances in Experimental Medicine and Biology Volume 754, 2013, pp 253-
283 (112). 
 
Treatment of non-malignant cells with DAC leads to altered gene transcription 
(113) and can be used as an epigenetic modulator. It is noteworthy that DAC 
has also been associated with mutagenesis, i.e. point mutations and genome 
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rearrangements in murine fibroblasts (114).  
4.8.1 Epigenetics in Cancer 
The importance of epigenetics in cancers has been described for altered DNA 
methylation and histone modification. In cancer cells entire chromosomal 
segments may be densely packed as heterochromatin. Genes in these 
regions are inaccessible for the translation apparatus which consecutively 
leads to a silencing of genes encoded on these stretches of the genome. 
Silencing by altered packing has been described for tumour suppressor 
genes and their target genes (115, 116). Another mechanism of tumour 
suppressor gene silencing has been attributed to interfering RNA (117). Also 
aberrant gain of expression of oncogenes linked to promoter hypomethylation 
such as for pS2 a pleiotropic factor which is implicated in the control of cell 
proliferation (118) or of the homeobox gene HOX11 (119), but also loss of 
expression by hypermethylation of tumour suppressor genes such as p16 
(120) and MLH1, a gene of the DNA mismatch (MMR) complex involved in 
the carcinogenesis of colorectal cancer (121) have been described. 
Epigenetic inhibitors, so called EpiDrugs have recently been introduced for 
anti-tumour therapy (50).  
4.8.2 Epigenetics in tumour stroma 
Epigenetic changes have been described in non-malignant tumour stromal 
cells of various cancers. Epigenetic variation at the DNA level has been 
documented in stromal fibroblasts of breast cancer (122), prostate cancer 
(123), gastric cancer (109, 124) colorectal cancer (85) and non-small cell lung 
cancer (NSCLC) (108). Epigenetic regulation of microRNA (miR)-200 which is 
regarded as an epigenetic modulator itself has been described in cancer 
associated fibroblasts in gastric cancer where it is involved in cancer 
progression (125) and work published by the group has shown that miRNA 
profiles differ between CAM and ATM (87).  
Epigenetic activation of the TGFβ signalling through SMAD3 silencing by 
promoter hypermethylation leads to a hyper responsiveness to exogenous 
TGFβ1 stimulation and increased contractility and extra cellular matrix 
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deposition by CAF (108). 
4.9 Gastrointestinal tumours and oesophageal cancer 
The gastrointestinal (GI) tract can include the digestive organs (oral cavity, 
oesophagus, stomach, duodenum, jejunum, ileum, caecum with appendix, 
colon and rectum) and connected organs (liver & pancreas). The GI tract 
gives rise to a wide variety of tumours of epithelial, haematopoietic and 
stromal differentiation, with epithelial being the most common type. Various 
different risk factors such as smoking, alcohol, obesity, infections and 
geographical location are currently recognised by the WHO for the different 
organs (126). 
Oesophageal tumours account for the 14th most common tumour type in the 
UK and oesophageal cancers are the eighth leading cause of cancer and the 
sixth most common cause of cancer-related death worldwide (127, 128). 
The majority of the tumours are epithelial in nature and develop from 
precursor lesions of the mucosa (dysplasia/intraepithelial neoplasia, low and 
high grade) to invasive carcinomas. The majority of oesophageal cancers are 
squamous cell carcinomas (OeSCC). OeSCC are related to alcohol 
consumption and smoking (129). Alcohol decreases detoxification and 
promotes oxidation in the oesophageal microenvironment. Alcohol is a 
solvent that increases the permeability of tobacco derived toxins and 
promotes carcinogens. A second large group derives from metaplastic 
Barrett’s epithelium with different grades of dysplasia dedifferentiating into 
invasive adenocarcinoma or Barrett’s carcinoma (OeAC). Barrett’s metaplasia 
is related to acid and bile reflux into the oesophagus known as gastro-
oesophageal reflux disease (130). Barrett’s adenocarcinoma of the 
oesophagus is distinct from its counterparts in the stomach and exhibits 
increased incidence in Western countries (131).  
The WHO provides a more elaborate classification for tumours of the 
oesophagus and the oesophagogastric junction beyond OeSCC and the 
OeAC. The current (published in 2010) WHO list of tumours of the 
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oesophagus includes adenoid cystic carcinoma, adenosquamous carcinoma, 
basaloid squamous cell carcinoma, mucoepidermoid carcinoma, spindle cell 
(squamous) carcinoma, verrucous (squamous) carcinoma and 
undifferentiated carcinoma. The WHO further lists neuroendocrine neoplasms 
and mesenchymal tumours and lymphomas. Metastases from other sites are 
also not uncommon (126). 
4.10 Investigating the tumour microenvironment 
4.10.1 Addressing the tumour microenvironment in vitro 
In order to investigate the tumour microenvironment, models which 
supposedly mimic the human disease have been generated and are widely 
used. For every pillar which Hanahan and Weinberg cite in their review 
various in vitro models addressing the same questions have been generated. 
Most models are based on basic cell culture systems with different nuances. 
Chamber systems have been developed to study migration and chemotaxis. 
Artificial barriers can be used in order to study invasion. The limitation of all 
these models are that they do not perfectly mirror the reality in vivo. 
4.10.2 Addressing the tumour microenvironment in vivo 
Studying tumours in live animals, i.e. in vivo has the advantage that all 
cellular components occurring in the tumour microenvironment can be 
observed in a four dimensional context. In vivo models are closer to events 
occurring in humans than in vitro conditions. Numerous models which 
replicate the accumulation of genetic defects in specific organs leading via 
dysplasia to invasive cancer exist (132). Chemically inducible models do also 
exist for oesophageal cancer (133). The modulation of the immune system in 
mice has allowed implantation of tumours notwithstanding the species barrier. 
The investigation of human derived cancers in vivo as xenografts or 
xenotransplants have become a pillar of drug development. These models 
are most useful in order to study drug related effects on tumour growth. 
Animal models are prone to higher biological variability and require ethical 
considerations. Furthermore the host immune system does not correlate with 
the human condition. Humanised animal models where human bone marrow 
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has been xenotransplanted have been established in order to better mimic 
reality (134). 
4.11 Wnt/β-catenin signalling  
Wnt/β-catenin is a key cellular regulator of gene expression. At least three 
pathways of Wnt signalling have been described in mammalian cells: A) the 
Wnt/β-catenin (also known as canonical) pathway, B) the planar polarity 
pathway which regulates cell polarity in the plane in developing tissues, and 
C) the Wnt/Ca2+ pathway which is involved in intracellular Ca2+ homeostasis. 
An initial binding of Wnts to receptors of the Frizzled family and it’s co-
receptor low-density lipoprotein receptor related protein 5 or 6 occurs in all of 
the three pathways which leads to a recruitment of Dishevelled to the trans 
membrane receptor and a consecutive binding of the Axin complex to the 
membrane. In the canonical Wnt/β-catenin pathway Wnt acts as a 
transcription activator. In the absence of Wnt signalling unbound β-catenin is 
phosphorylated by the Axin complex which consisting of the two protein 
kinases glycogen syntase kinase 3 (GSK3), a serine/threonine kinase casein 
kinase 1 (CK1) and the two scaffold protein Axin and Adenomatous polyposis 
coli (APC). Upon phosphorylation β-catenin is degraded through the ubiquitin 
disintegration process. Phosphorylation and ubiquitination of β-catenin 
through the Axin complex is supressed and β-catenin instead transported to 
the nucleus where it acts as a transcription activator by binding to the T cell 
factor/lymphoid enhancer factor (TCF/LEF) family of proteins. Nuclear 
accumulation of β-catenin is hence a surrogate marker for Wnt signalling 
pathway activation. For reviews see (135, 136). 
4.12 Secreted frizzled related proteins and Wnt-signalling 
Secreted frizzled related proteins (SFRP) act as soluble modulators/inhibitors 
of Wnt signalling pathway by competing with Wnt for the cell surface receptor 
Frizzled binding site (137-140). As inhibitors of the Wnt pathway SFRPs are 
key-players in developing organs such as oesophageal epithelia (141). 
Unsurprisingly loss of SFRP expression has been associated with a variety of 
tumours. Downregulation of SFRP expression has been related to promoter 
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hypermethylation in premalignant and malignant tumours of various organs. 
Downregulation of SFRP genes was observed as an early event in adenoma 
development in the colonic mucosa (142, 143). Silencing of SFRP genes has 
been described in urothelial carcinoma (144), renal cell carcinoma (145), 
squamous cell carcinoma of the oral cavity (146), gastric cancer (147), 
basaloid squamous cell carcinoma of the oesophagus (148), colorectal 
cancer (149, 150) and malignant mesothelioma (151). Altered methylation of 
this gene is a potential biomarker for colorectal cancer (152, 153). 
Kaur et al describe in a recent study that SFRP2 expression in the tumour 
microenvironment is age-related. In their work on malignant melanoma they 
observed that stromal cells from young patients have a different effect on 
tumour growth and metastasis. Whereas young stromal cells lead to an 
accelerated tumour growth, aged fibroblasts showed a SFRP2 dependent 
increase in invasion, angiogenesis and metastasis (154). This data underlines 
the importance of stromal cells and their epigenetic modification during aging 
and tumourigenesis.  
4.13 Paired-like homeodomain transcription factor (PITX) 2 
PITX2 is located on 4q25 and belongs to the RIEG/PITX homebox family - as 
such it is a bicoid homeodomain protein. PITX2 acts as a transcription factor 
and down-stream effector of the Wnt/β-catenin signalling pathway leading to a 
cell type specific regulation of proliferation. It has been shown to regulate the 
Wnt/beta-Catenin pathway in ovarian carcinoma cell lines (155).  
Several genes involved in cell migration, adhesion and motility have been 
identified as PITX2 targets. These include microtubule stabilization, actin 
cross-linking and tubulin related and intermediate filaments (156). These data 
suggest that myogenic cells have large single protrusions with a highly 
directed migration by continuous remodelling of their cytoskeleton and 
stabilization of their adhesion to the extracellular matrix. PITX2 can regulate 
myogenic cell migration by influencing their polarity and shape by restricting 
the microtubule growth and providing membrane and associated proteins 
needed for forward protrusion, fusion and muscle formation (156).  
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PITX2 is involved in the determination of left-right symmetry during 
development. It controls cell proliferation in a tissue-specific manner and is 
involved in morphogenesis and myogenesis by direct regulation of the 
expression of a number of cyclin-dependent kinases (157). It is involved in 
cell motility in craniofacial development (158).  PITX2 has been shown to be 
associated with different histone H3 lysin 4 methylatransferase (HKMT) 
subunits and to regulate the procollagen lysyl hydroxylase gene expression 
(159). 
Mutations of PITX2 are associated with atrial fibrillation and ocular and dental 
malformation such as the Axenfeld-Rieger syndrome which can involve other 
systemic abnormalities such as craniofacial dysmorphism with maxillary 
hypoplasia (160). Furthermore aberrant hypermethylation of PITX2 in 
adenocarcinoma of the prostate has been shown to be an independent 
adverse prognostic factor for recurrence (161).   
4.14 Aim of this work 
The specific aims of this thesis were to establish whether oesophageal CAMs can be 
defined by their epigenetic trait. We therefore assessed whether CAMs and ATMs 
differ at a global DNA methylation level. We further decided to address this question 
by investigating site specific altered DNA methylation using array technology. The 
primary objective was to identify candidate loci (CpG islands, CpG shores and 
differentially methylated regions (DMRs)) with altered DNA methylation that can be 
linked either positively or negatively to the mechanisms by which CAMs influence 
cancer cell function. The methylation array data were then to be validated by 
pyrosequencing and three differently methylated genes with correlating altered 
expression to be selected (ADAMTS12, PITX2 and SFRP2) for investigations on 
their biological role in CAMs by overexpression and knock-down studies.  
A second aim was to assess whether myofibroblasts can be epigenetically modified 
in vitro and whether this would influence tumour growth. In order to assess whether 
myofibroblasts are targets of epigenetic modification at DNA methylation level, we 
treated myofibroblasts with DAC, a DNA methyl transferase inhibitor. We assessed 
whether DAC treatment would lead to a modification of DNA methylation and alter 
the cellular phenotype which can be passaged and hence regarded as being 
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epigenetically inherited. We further wanted to investigate whether epigenetic 
modification of the tumour stromal myofibroblasts would influence tumour growth in 
vitro and in vivo. We therefore studied tumour growth in a xenograft model where we 
co-injected epigenetically modified myofibroblasts. 
A third aim was to study the fate of myofibroblasts in xenografts. To address the role 
of myofibroblasts co-injected in xenograft studies we investigated myofibroblasts at 














5.1 Ethical approval 
5.1.1 Human primary cell lines 
The harvesting of, and work on, primary human myofibroblasts was approved 
by the Ethics Committee of the University of Szeged, Hungary and stands in 
accordance with the Human Tissue Act (162). 
5.1.2 Animal work 
Mice were kept, and all procedures performed, in accordance with the Animal 
Act 1986 (163). 
5.2 Eukaryotic cell culture 
5.2.1 Eukaryotic cells 
Cells were cultured in filter-vented plastic flasks at 37°C in high humidity 
incubators with 5 % v/v CO2. All myofibroblast cell lines and all cancer cell 
lines were grown in complemented myofibroblast medium (MM) which is 
Dulbecco’s Modified Eagle’s Medium, glucose (4500 mg/L), L-glutamine, and 
sodium bicarbonate, without sodium pyruvate, supplemented if not otherwise 
stated with 10 % foetal bovine serum (FBS), 2 % antibiotic antimycotic 
solution (A/A), 1 % penicillin/streptomycin and 1 % non-essential amino acids.  
Cells were passaged at 90 % confluence in a ratio of 1:2 or 1:3 depending on 
their growth behaviour. For passaging, cells were washed with 1x phosphate 
buffered saline (PBS), followed by proteolysis with 1 x trypsin/ethylene 
diamine tetraacetic acid (EDTA). The activity of trypsin was subsequently 
quenched by the addition of MM.  
5.2.2 Cancer cell lines  
Oesophageal cancer cell lines (OE19, OE21, OE33 (164)) were adapted to 
MM.  
5.2.3 Primary human myofibroblasts 
Primary human myofibroblasts had previously been isolated by the out-growth 
method as described by Wu et al in 1999 for stromal cells of the gastric 
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mucosa (95, 165, 166). Most myofibroblast lines had been isolated by 
Professor Peter Hegyi, University of Szeged, Hungary and have been 
described in several publications (73, 81, 94, 95, 97, 167-170). Three types of 
myofibroblast were used, namely CAMs, ATMs and NTMs. CAMs were 
isolated from the macroscopic tumour bulk whereas ATMs derive from 
macroscopically normal appearing tissue 1 cm away from the tumour bulk 
(figure 1). NTMs derived from tumour free individuals (transplant donors). Cell 
counting was performed with use of a Neubauer Zählkammer. 
5.2.4 Transwell migration assay 
Transwell migration assays were performed using Boyden chamber (171) 
inserts with 8 µm pores. Cells were harvested with trypsin/EDTA and trypsin 
activity then quenched with 0.1 % FBS in cell culture medium. The cells were 
kept on ice for further processing. The appropriate number of cells was 
transferred into a 50 ml screw cap tube and centrifuged for 7 min (800 x G, 
4°C). The supernatant was then carefully removed and the cells suspended in 
Dulbecco’s modified Eagle’s medium (DMEM) (for OE21 cells 100,000 cells, 
for myofibroblasts 40,000 cells per ml). Test medium (750 µl) was added to 
the individual wells and the cell suspension to the chamber inserts. Cells were 
allowed 16 h to migrate to the outer face of the Boyden chamber through the 
8 µm pores in the membrane. The inserts were removed, media discarded 
and the inner face of the membrane wiped with a wet Q-tip to remove cells 
which had not migrated. Membranes were then stained using a Quick-Diff kit. 
In brief, cells were fixed for 8 min, followed by sequential staining with red and 
blue dyes for 5 and 4 min respectively. Inserts were then washed with water. 
Excess water was removed and the membranes dried in air. Finally, 
membranes were excised using a pointed scalpel blade and mounted on a 
glass slide using mounting medium. Migrated cells in five low power fields 
were counted.  
5.2.5 Ibidi® chamber systems 
Ibidi® silicon two chamber systems with a defined gap of 500 µm between the 
chambers were used for time lapse video microscopy. The self-adherent 
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ibidi® chambers were attached to 12 well tissue culture plates. Into one 
chamber 80 µl of OE21 cells (1.25 x 105) were plated, and myofibroblasts (2.5 
– 6.25 x 105) were plated into the other. Cells were then allowed to adhere 
(18 h for cancer cells, 8 h for myofibroblasts) after which 2 ml of serum-free 
medium was added to the well, and the chamber carefully removed using 
forceps. The wells were then washed twice with serum-free media. For 
migration studies, fresh supplemented DMEM with 2 % FBS was added.  
5.2.6 Cell proliferation assay by EdU incorporation 
Visualisation of integrated 5-ethynyl-2’-deoxyuridine (EdU) into DNA during 
the S-phase of the cell cycle by the “click” reaction (172)  was used to assess 
proliferation rates (173). Click-iT® EdU Alexa Fluor® 488 or 594 imaging kit 
were used. In brief, cells 1 – 2 x 104 myofibroblasts or 2 – 4 x 104  cancer 
cells were plated on glass cover slips in a 24 well plate. Cells were incubated 
with 10 µM EdU in MM (60 min for cancer cells and 24 h for myofibroblasts), 
rinsed thereafter with PBS and fixed for 30 min in 10 % formalin. The cells 
were then permeabilised with TBS with 0.5 % Triton X-100 for 10 min and 
washed thereafter twice with PBS. Cells were then incubated with freshly 
prepared Click-iT ™ reaction mix consisting of 1 x Click-iT™ reaction buffer, 
4 % copper sulphate and 1 x reaction buffer for 30 min. The samples were 
washed twice for 5 min with PBS and either mounted on glass slides with 
Vectashield® plus 4,6-Diamidin-2-phenylindol (DAPI) or further processed 
according to the immunofluorescence protocol sparing the permeabilisation 
and the BSA blocking step. The number of nuclei labelled with DAPI and 
proliferating cells tagged with Alexafluoracids linked to EdU were assessed by 
fluorescent microscopy and the total number of cells were counted in a 400x 
magnification field. 
5.2.7 Cell expansion assay 
Upon DAC treatment in 75 cm2 flasks myofibroblasts were harvested and 
5000 plated on glass cover slips in triplicates on 24 well plates. 
Myofibroblasts were then grown in 10 % MM until confluence was reached in 
one of the samples. Cells were then stained using the Quick Diff staining 
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system and mounted on glass cover slips. Slides were then scanned with a 
conventional high definition (HD) scanner.  
5.2.8 Gel contraction assay 
Gels were set up on ice. Samples were prepared as triplicates of gel-cell 
mixes. For each sample 800 µl of collagen I (3.5 – 4.5 mg/ml), 100 µl 10 x 
DMEM, 80 µl of water, 20 µl of 1 M NaOH and 1.0 ml of cell suspension 
(80,000 cells per ml in DMEM) were mixed by pipetting. Into wells of a 24 well 
plate 500 µl of the liquid gel-cell mixture were added and left in the incubator 
for the gel to solidify. Thereafter gels were detached with a pipette tip and 
500 µl of DMEM were added to each well. Macroscopic pictures were taken at 
different time points and area change as an indirect measure for cell 
contraction was assessed in imageJ. The decrease of contraction area over 
time was used as an indicator for cell contractibility. 
5.2.9 Organotypic culture (experiment performed by Dr Kumar)  
Organotypic cultures were grown as described previously (174, 175). In brief, 
OE21 cells (1 x 106) were seeded on top of 1 : 1 Matrigel/collagen-I with or 
without myofibroblasts (0.5 x 106) suspended in the gel. On day 3, the culture 
was raised on wire gauze and maintained at an air medium interface for 15 
days, changing medium every 48 h. Cultures were fixed in 10 % neutral- 
buffered formalin and paraffin-embedded sections were stained with H&E. 
Invasion was determined by measuring the depth of invading cancer cells into 
the Matrigel. A total of eight measurements were taken per field and 18 fields 
were captured per group at 100x magnification.  
5.2.10 5’Aza - 2’deoxy cytidine toxicity assays 
DAC was suspended in DMSO to a stock concentration of 10 mM and kept at 
-80° C. DAC stock solution was diluted in MM for treatment. Treatment of 
myofibroblasts with DAC was performed as follows: 0.5 x 106 cells were 
plated in a 75 cm2 tissue culture flask and allowed to adhere overnight and 
the medium then exchanged. One day later cells were treated every 24 h for 
three consecutive days with DAC diluted in MM, and diluted DMSO as 
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controls. The cells were then washed with PBS and incubated for another 24 
hours with MM before further use (figure 3). 
 
Figure 3: 5’Aza-dC treatment scheme. Myofibroblasts were seeded and 
treated on three, six or nine consecutive days. Thereafter all cells were grown 
in control media. 
 
Demethylation treatment was performed with DAC concentrations varying 
from 0.001 µM to 10 µM in MM, every 24 h after initial seeding for 3, 6 or 9 
days. Upon the last treatment cells were washed with serum free medium 
twice and then kept in culture in MM.  
5.2.11 Fluorescent cell labelling 
Myofibroblasts and cancer cells were labelled using a hydrophobic cell linker 
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Fluorescent Cell Linker (176, 177) were used. Briefly, 2 x 107 cells harvested 
as described above, were centrifuged (6 min 600 x G at 20°C) and the 
supernatant removed. The cell pellet was then suspended in 10 ml of DMEM 
and centrifuged a second time (400 x G for 5 min at 20°C). The supernatant 
was then entirely removed and the pellet suspended by gentle pipetting in 
1 ml of Diluent C of the kit. Thereafter 1 ml of 40 µM of the fluorescent dye 
diluted in Diluent C was added to the cell suspension and mixed by pipetting. 
The cell/dye suspension was then incubated at room temperature for 2 min 
before 2 ml of 10 % MM were added in order to bind excess dye. Cells were 
then centrifuged at 400 x G for 10 min at 20°C, the supernatant discarded and 
the pellet resuspended in 10 ml of 10 % MM. Excess dye was removed by 
two consecutive steps of pelleting by centrifugation (400 x G for 5 min at 
20°C) and resuspension in 10 % MM. Cells were then plated in 75 cm cell 
culture flasks and used for experiments or cryopreserved two days after 
labelling.  
5.2.12 Endothelial tube formation assay 
Endothelial tube formation/sprouting angiogenesis assays (178-180) were 
performed according to the protocol from Life Technologies 
(http://www.lifetechnologies.com /uk /en /home /references /protocols /cell-
and-tissue-analysis/ cell-profilteration-assay-protocols/ angiogenesis-
protocols/ endothelial-cell-tube-formation-assay.html). 
Briefly, human umbilical vein endothelial cells (HUVEC) were grown in 
supplemented endothelial basal medium (EBM) until 80 % confluent. Matrigel 
(Geltrex™) was thawed at 4°C overnight and kept on ice before plated into on 
ice pre-chilled 24 or 96 well plates (50 µl/cm2 for 24 well plates, i.e. 95-100 µl 
per well and 100 µl/cm2 for 96 well plate, i.e. 30-40 µl per well). The gels were 
then incubated at 37°C for 30 min to solidify. In the meantime HUVECs were 
harvested as described (5.2.1) and resuspended in serum free MM. The 
number of cells needed were pipetted into a 1.5 ml Eppendorf® tube and 
pelleted by centrifugation (6 min at 600 x G). The pellet was then re-
suspended in CM (harvested as described; 8 x 104 cells per ml) and 200 µl 
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HUVEC suspension were plated per cm2. Cells were then allowed to 
sediment and adhere in the humidified incubator at 37°C. After one hour, 
which was defined as time point zero (t0), photomicrographs were taken at 
defined intervals (every 20 min for time lapse microscopy, t0 +1, +2, +3, +4, 
+6). Images were analysed using ImageJ software 1.50 with the use of the 
Angiogenesis Analyser plugin (181). 
5.2.13 Conditioned medium 
CM  was harvested as described previously (95). Briefly, for CM from 
myofibroblasts and OE21 cells, 0.5 x 106 or 3 x 106 cells respectively, were 
plated in MM in a 75cm2 TTP tissue culture flask (i.e. 6,666 cells/cm2 for 
myofibroblasts and 4 x 104 /cm2 for OE21 cells). After 24h, cells were washed 
three times with PBS. Thereafter 10 ml of DMEM was added (133 µl/cm2). 
After 24 h in culture, media were collected and centrifuged for 7 min at 
800 x G at 4°C. The supernatant was then carefully removed, aliquoted and 
stored at -80°C.  
5.2.14 Transfection of myofibroblasts by electroporation 
Myofibroblasts were transfected by electroporation (182) using the 
Nucleofector™ system from Lonza. Briefly, myofibroblasts were harvested as 
described and 5.5 x 105 cells pelleted by centrifugation at 4°C for 6 min at 
800 x G. Cells were then suspended in 100 µl Amaxa™ Fibroblast 
Nucleofector medium together with 3 µg of DNA or siRNA. The cell 
suspension was electroporated using program U-23 on the Amaxa® 
Nucleofector instrument. After electroporation, 500 µl of MM was added to the 
cuvette and the suspension transferred into a tissue culture flask containing 
pre-warmed MM.   
5.3 Prokaryotic cells 
5.3.1 Transfection of bacteria 
Competent bacteria (NEB Turbo Competent E. coli) were thawed on ice for 
20 min and 10 ng of plasmid DNA in 5 µl of TE buffer (10 mM Tris 0.1 mM 
EDTA) was added and the tube mixed. Bacteria were then left for 30 min on 
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ice, heat shocked for 30 sec at 42°C and chilled immediately on ice for 5 min. 
Ambient temperature super optimal broth with cataboite repression 
(SOC) medium (950 µl) was added and incubated at 37°C under vigorous 
shaking (250 rpm) for 60 min. Serial dilutions of the primary bacterial culture 
were spread on antibiotic containing agar plates. After 16 h single colonies 
were picked and expanded for 16 h in 6 ml antibiotic containing LB medium.  
5.3.2 Bacteria culture 
Bacteria were cultured on 10 cm Petri dishes with agar or in lysogeny broth 
(LB) medium (on a shaker) containing kanamycin (25µg/ml) or ampicillin 
(100µg/ml) at 37°C. 
5.3.3 Glycerol Stocks 
Glycerol stocks of all E. coli cultures were generated by adding 200 µl of 
glycerol to 800 µl of cultured bacteria and mixed gently by pipetting. Cells 
were stored at -80°C.  
5.3.4 Screening for plasmid 
Expanded primary bacteria cultures (200 µl) were incubated for 5 min at 95°C 
and centrifuged for 2 min at > 9000 x G. The supernatant (5 µl) was used for 
Q-PCR amplification (for Q-PCR see 3.5.10). Bacterial cultures providing a 
positive Q-PCR result were used for mini-prep plasmid extraction. 
5.3.5 Plasmid extraction 
MiniPrep: For screening, plasmid DNA was isolated using the Zyppy™ 
Plasmid miniprep kit from Zymo Research according to the manufacturers 
instructions. Briefly, 600 µl of bacteria cultures grown in LB medium were 
lysed with 100 µl of 7x Lysis Buffer and mixed by inverting the tubes. The 
reaction was neutralized by admixing of 350 µl of neutralization buffer and the 
denatured proteins/lipids pelleted by centrifugation at 12,000 x G for 2 min. 
The supernatant was transferred into Zymo-Spin™ columns and then 
centrifuged for 15 sec at 12,000 x G. The samples were then washed with 
200 µl of endo-wash buffer followed by a 30 sec centrifugation and 400 µl of 
Zyppy™ wash buffer for 1 min. Flow troughs were discarded in between 
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centrifugation steps. After the final wash step the sample was centrifuged for 
an additional 4 mins at 12,000 x G. Plasmid DNA was eluted with 30 µl of 
Zyppy™ elution buffer.  
MaxiPrep: ZymoPURE™ Kit from Cambridge Biosciences was used for 
plasmid extraction according to manufacturers protocol. Briefly, bacteria were 
pelleted by centrifugation for 10 min at 3000 x G and resuspended in 15 ml of 
P1 buffer. Cells were then lysed for 1 min by admixing 15 ml P2 lysis buffer. 
The process was stopped by the addition and incubation of 20 ml P3 
Neutralisation buffer for 5 min. The mixture was then added onto Zymo-Maxi 
Filter™/Zymo-Spin™ VI columns and assembled on a vacuum manifold. After 
the precipitate was left to float to the top vacuum was then applied and all 
liquid left to pass completely through both columns. The upper filter was 
removed and the filter on the lower column washed with 10 ml of endo wash 
buffer and then additionally centrifuged with 3,400 x G for 5 min before elution 
of the plasmid DNA with 2 ml of Zyppy™ elution buffer by centrifugation at 
3,400 x G for 1 min.  Plasmid DNA quality and concentrations were assessed 
by spectrophotometry as described. DNA was concentrated with a vacuum 
spin manifold in order to reach concentration above 500 ng per µl. 
5.4 Animal work 
5.4.1 Housing 
All animals were purchased and kept in the Biomedical Service Unit at the 
University of Liverpool in specific pathogen-free conditions. All animals used 
in the experiments were immunocompromised athymic Balb/C nu/nu mice 
(183). Animals were kept in groups of four per cage. In each experiment 
same gender animals were used. All animals had reached the age of 7 weeks 
and were acclimatised to the facility for 10 days before the start of an 
experiment. The work was approved by the University of Liverpool Animal 





Human cells were xenografted as previously described (94). Briefly, cells 
were harvested as described, and processed on ice. Cells were washed twice 
(pelleting by centrifugation at 600 x G for 6 min at 4°C) with PBS, and then 
diluted in PBS. Depending on the experiment, cancer cells and myofibroblasts 
were mixed to a final concentrations between 105 – 107 cells per ml. Cell 
suspensions were then injected subcutaneously (100 µl per site) using 25 
gauge needles. Before injection the cell suspension was mixed in order to 
maintain equal cell numbers. After injection tumour diameters were assessed 
regularly by calliper and tumour volumes calculated. Tumour volume was 
estimated by using the equation v = (ab2)/2, in which ‘v’ is volume, ‘a’ is the 
length of the major axis, and ‘b’ is the length of the minor axis (68). 
5.4.3 Gavage 
Mice were treated by gavage (100 µl) with 400 µmol.kg-1 omeprazole in 
aqueous 3 % methyl cellulose every 48 h. Gavage was started one week 
before xenografting. Methyl cellulose was prepared by heating water (200ml) 
to 90°C and adding methyl cellulose (6 g) with vigorous mixing until the 
powder was dispersed. The suspension was cooled to 4°C in order to allow 
methylcellulose to solubilise (below 60°C). 
5.4.4 Blood and tissue sampling  
Mice were euthanized by CO2 inhalation followed by cervical dislocation. 
Blood was obtained by cardiac puncture using a heparinised needle. Blood 
samples were stored on ice before centrifugation (3 min, 1000 x G). The 
plasma supernatant was harvested and frozen at -20°C until further use. 
5.5 Histological methods 
5.5.1 Processing of tissue 
Fresh tissue was kept on a wet gauze in a 10 ml flask on ice before being 
embedded in optimal cutting temperature (OCT) compound and being snap 
frozen with liquid N2. Tissue samples for paraffin embedding were fixed in 
10 % buffered formalin for at least 12 h before embedding. Paraffin 
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embedding, sectioning of paraffin blocks and staining (haematoxylin/eosin 
and alcian blue - periodic acidic shift) was carried out by the Histology 
Laboratories of the Veterinary School of the University of Liverpool.  
Snap frozen tissue was cut into 5 µm sections and mounted on glass slides. 
Slides were air dried and kept at -80°C until further use.  
5.5.2 Haematoxylin and eosin staining (H&E) 
Snap frozen tissue slides were fixed in acetone and washed in alcohol before 
staining in haematoxylin for 5 min. The slides were then rinsed under the 
warm running tap until a bluish stain became apparent. The stain was 
differentiated by immersing three times in 1 % hydrochloric acid/70 % ethanol. 
Slides were counterstained with 1 % eosin for 1 min followed by rinsing under 
the tap and dehydration through an increasing ethanol series (70 % - 90 % - 
96 % - 100 %) and then drying in air. Coverslips were mounted with mounting 
medium.  
5.5.3 Immunofluorescence (IF) 
For immunofluorescence 22 mm glass cover slips were added into individual 
wells of 24 well plates and sterilisd by UV irradiation. Cells were suspended in 
10 % MM (5000 myofibroblasts or 10,000 cancer cells per cm2) on 22 mm 
glass cover slips and allowed to adhere for 24 to 48 h. After fixation cover 
slips containing cells or glass slides with tissue sections were washed with 
PBS (phosphate buffered saline) and fixed with 10 % formalin for 30 min. 
Slides were then washed twice with PBS and permeabilised with PBT (for 
buffers see 6.8) at room temperature for 30 min followed by two washes with 
PBS. Non-specific binding of the secondary antibody was inhibited by 30 min 
blocking with 10 % serum of the species of the secondary antibody. Slides 
were then washed twice with PBS and the primary antibody dissolved in PBS 
incubated for 1 h at room temperature or overnight at 4°C (for dilutions of the 
primary antibody see table 1). Samples were then rinsed with PBS, followed 
by washing with 0.14 M NaCl, 0.5 M NaCl and PBS for 10 min each. The 
secondary antibody diluted in 10 mM HEPES pH 7.5 was incubated for 1 h at 
room temperature. Samples were then rinsed with PBS and incubated for 
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5 min with DAPI diluted in PBS, followed by washes with PBS, 0.14 M NaCl 
and PBS for 10 min each time. Cover slips were mounted on glass slides with 
Vectashield®.  
Table 1: antibodies for immunofluorescence 
 
5.5.4 Fluorescent in situ hybridisation (FISH) 
FISH of human centromeres was performed according to the protocol G1 
from StarFISH®. Briefly, tissue sections were fixed in 3:1 ethanol:acetic acid 
for 30 min and then dried. In order to remove the acid the slides were passed 
through a graded ethanol series (70, 90, 100 %) and air dried before baking 
at 65°C for 15 min. After cooling to ambient temperature slides were 
incubated in acetone for 10 min followed by air drying. In order to remove 
RNA, slides were treated for 60 min at 37°C with RNase (100 µg/ml) in 
2 x SSC followed by two washes with 2 x SSC for 5 min each. The slides 
were then immersed in 10 mM HCl followed by a 2 min digestion with pepsin 
(1 mg/ml) in 10 mM HCl in a slide staining jar at room temperature. The 
digestion was stopped by immersing the slides in 1 x PBS followed by 
dehydration through an ethanol series and then air drying. In order to 
denature, the cellular DNA slides were immersed for 2 min in 70 % formamide 
in 2 x SSC. Thereafter slides were dehydrated through an ethanol series and 
air dried. A circle was scratched around the tissue specimen on the slide with 
a diamond pen.  
The probe was thawed, vortexed and denatured for 10 min at 85°C and 
immediately chilled on ice. Probes (10 – 20 µl) were added to the section and 
covered with a purpose cut glass cover slip and then sealed to the glass slide 
with rubber glue. The hybridisation was carried out over 16 h in a humidified 
chamber at 37°C. Post hybridisation washing after removal of the cover slips 
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was carried out as follows: initial washing for 5 min at 37°C in 2x SSC, 
followed by two washes for 5 min in 50 % formamide / 2 x SSC at 37°C. The 
slides were then washed twice for 5 min in 2 x SSC. Slides were then 
mounted with Vectashield® with DAPI and sealed with nail varnish.  
5.5.5 Combined IF and FISH (I-FISH) 
After completion of the FISH test, the antibody incubation was performed on 
the specimen as described in the immunofluorescence labelling protocol 
(5.5.3), without the permeabilisation step with 0.5 % TBE. At the end the 
slides were mounted with Vectashield® with DAPI and sealed with nail 
varnish.  
5.5.6 Microscopy 
Bright field and fluorescent microscopy were carried out on a Zeiss Axiopan 2 
microscope. Image acquisition was performed using Zeiss AxioVision 3.1 
software. 
5.5.7 Quantification of histology: 
Histology grading was semi quantitatively assessed on H&E stained formalin-
fixed and paraffin embedded (FFPE) sections for inflammation, fibrosis, 
nesting (engulfment of cancer cells by myofibroblasts), necrosis, 
keratinisation and presence of myofibroblastic cells based on a four-tiered 
scale (0 = absent, 1 = few, 2 = intermediate, 3 = abundant).  
5.5.8 Time lapse microscopy 
Time lapse microscopy was performed on a LEICA DMIRE2 microscope 
controlled and pictures captured with a Hamamatsu camera. Images were 
processed using Metamorph and imageJ software (184). The outgrowth area 
of cells into the empty gap space or the gap space was measured with 
ImageJ at 6, 18, 18 and 24 h after removal of the chamber inserts. 
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5.6 Nucleic acids related molecular biology techniques 
5.6.1 DNA extraction 
DNA was extracted using an adapted version of the QIAamp®  DNA mini Kit. 
Briefly, cells from confluent 75 cm² tissue culture flasks (no more than 5x106) 
were harvested and re-suspended in 200 µl PBS. After pipetting 20 µl of 
protease K to the bottom of a 1.5ml centrifugation tube, the cell suspension, 
4 µl of RNAse (100 mg/L) and 200 µl of buffer AL were added. The sample 
was digested overnight at 56°C on an Eppendorf thermomixer. After digestion, 
tubes were centrifuged briefly, 200 µl of molecular grade ethanol (>98 %) 
added, the samples shaken for 15 sec and then centrifuged briefly. The lysed 
and digested cell suspension was then added to a QIAamp mini spin column 
inserted into a 2ml collection tube and centrifuged at 6000 G for 60 sec. After 
centrifugation, the spin column was placed in a new 2ml collection tube, 
500 µl of buffer AW1 was added and the samples centrifuged at 6000 x G for 
60 sec, followed by insertion into a new collection tube with a further 500 µl of 
buffer AW2 and centrifugation at 20,000 x G for 3 min. The spin column was 
then placed in a clean collection tube and centrifuged for another minute at 
20,000 x G to elute ethanol remnants. The spin column was then placed in a 
clean 1.5ml collection tube and 80 µl of pre-warmed (42°C) buffer AE was 
added onto the filter. After 5 min the column was centrifuged at 6000 x G for 
one minute and the eluate kept on ice until further processed.  
5.6.2 Assessment of DNA quality by spectrophotometry 
DNA concentration and quality were assessed by measuring absorbance at 
260 and 280 nm using a NanoDrop 2000c spectrophotometer. The quality 
was considered appropriate when the ratio A260/A280 nm (A260/A280) was 
greater than 1.75; A280 of 0.1 - 1 was regarded as suitable for further 
processing.  
5.6.3 RNA extraction 
RNA was extracted using the QIAGEN® miRNeasy mini Kit according to the 
manufacturer’s instructions. Briefly, cells were lysed with 700 µl of QIAzol 
Lysis Reagent or Trizole and harvested with a cell scraper. The lysate was 
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incubated for 5 min at ambient temperature. Thereafter 140 µl of chloroform 
were added and the solutions mixed by vigorous shaking for 15 s. After 3 min 
incubation at room temperature, the sample was centrifuged for 15 min with 
12,000 x G at 4°C. The upper (aqueous) phase was then transferred into a 
collection tube and mixed by pipetting with 1.5 volumes of 100 % ethanol. 
Nucleic acids were then trapped on the filters of spin columns by 
centrifugation of the total aqueous phase in repeated steps. In order to 
remove DNA a column treatment with DNAse was performed. The sample 
was then purified with 700 µl of buffer RWT and twice 500 µl buffer RPE by 
centrifugation steps at 12,000 x G for 30 sec each. The spin columns were 
centrifuged one additional time at 12,000 x G for 3 min. The RNA was then 
eluted with 30 µl of RNase-free water by centrifugation at 8,000 x G for 1 min. 
RNA was stored at -80°C. 
5.6.4 Assessment of RNA quality by spectrophotometry 
RNA concentration and quality were assessed by absorbance at 260 and 
280 nm using a NanoDrop 2000c spectrophotometer. RNA was regarded as 
of appropriate quality when the ratio of A260/A280 was greater than 2.0 and the 
ratio of A260/A230 nm (A260/A230) were in the range of 2.0 to 2.2.  
5.6.5 Assessment of the RNA integrity number (RIN) 
The quality of RNA used for expression arrays was assessed by evaluation of 
the RNA integrity number (RIN) (185, 186) which is a measure of degradation 
of the RNA. The RIN was assessed with the Agilent 2100 Bioanalyzer and the 
corresponding Agilent RNA 6000 Nano kit. Firstly the electrodes of the 
bioanaylser were cleaned by incubation in 350 µl RNaseZAP per well for 
1 min followed by a 10 sec rinsing step with RNAse free water.  The chip was 
prepared according to the manufacturers protocol; briefly, all reagents stored 
at -80°C and -20°C were equilibrated to ambient temperature for 30 min, and 
gel matrix (550 µl) was loaded into the top receptacle of the spin filter which 
was then centrifuged for 10 min at 1500 x G and aliquoted (65 µl each) into 
0.5 ml RNase-free microfuge tubes. Aliquots were stored at 4°C. RNA 6000 
nano dye concentrate was vortexed for 10 sec, centrifuged and 1 µl pipetted 
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onto the filtered gel aliquot and mixed by vortexing. The tube was then 
centrifuged for 10 min at 13,000 x G. The gel-dye mix was allowed to 
equilibrate to room temperature protected from light. The chip was positioned 
on the chip priming station and 9 µl of the gel-dye mix were added to the 
bottom of the well “12” and dispensed (figure 4). The priming station was 
closed and the plunger of the syringe (positioned at 1ml) pressed down until 
held by the clip. After exactly 30 sec the plunger was released and 5 sec later 
slowly pulled back into the 1 ml position. Thereafter 9 µl of gel-dye mix were 
pipetted into wells 4 and 8. The RNA marker (5 µl each) was then added to 
wells 1-3, 5-8, 9-11 and 13-16. The RNA ladder was denatured for 2 min at 
70°C and before adding 1 µl into well 16. Then 1 µl of each sample or buffer 
was added into the sample wells (1-3, 5-8, 9-11 and 13-15). The chip was 
then vortexed for 60 sec at 2,400 rpm on an IKA vortex mixer and placed 
directly into an Agilent 2100 Bioanalyzer. The analyser program was set as 
default RNA quality. Quality of the run was regarded as successful when at 
least one RNA peak was demarked and the ribosomal 26s and 28s RNA was 
detectable and well resolved with correct peak size assignments in the 
electropherogram (figure 4). RNA quality was regarded as suitable for 
expression array analysis when the RIN number was 7.5 or higher. 
 
 
Figure 4: RIN setup and sample graph: Left: positions on chip. Right: 




5.6.6 Reverse Transcription 
RNA to DNA reverse transcription was performed with the High-Capacity 
RNA-to-cDNA™ Kit according to the manufacturer’s instructions. Briefly, a 
20 µl reaction mix consisted of 10 µl of 2x reaction buffer and 1 µl of 20x 
enzyme mix together with template RNA (1 – 2 µg) in 9 µl RNase free water. 
The reverse transcription was then performed on a thermo cycler by 
incubation at 37°C for 1 h, followed by a denaturation step at 95°C for 5 min. 
The sample was thereafter kept at 4°C before storage of aliquots at -20°C.  
5.6.7 Bisulfite conversion of DNA  
Bisulfite conversion (187) was performed using an adapted protocol of the EZ 
DNA Methylation-Gold™ kit. Briefly, 20 µl of DNA (50 ng/ µl) extracted 
according to the DNA extraction protocol was mixed with 130 µl of the CT 
Conversion Reagent. The bisulfite conversion was carried out in 200 µl 
reaction tubes on a Biorad® thermal cycler with the following steps: initial 
DNA denaturation (98°C, 10 min) followed by conversion (64°C, 150 min). 
After completion the samples were kept at 4°C for up to 16 h before mixing 
with 600 µl of M-binding in the Zymo-Spin™ IC columns.  The columns were 
then centrifuged for 30 sec at >10,000 x G. M-wash buffer (100 µl) was added 
and the filters washed by centrifugation (30 sec at >10,000 x G). 
Desulphonation was carried out by incubation with M-Desulphonation buffer 
(200 µl, 20 min, ambient temperature) followed by centrifugation (30 sec, > 
10,000 x G). The columns were then washed twice with 200 µl of M wash 
buffer followed by centrifugation (30 sec, > 10,000 x G). Bisulfite converted 
DNA was eluted with 40 µl of 42°C M-elution buffer. Samples were aliquoted 
and stored at -20°C. 
5.6.8 Polymerase Chain Reaction 
Polymerase chain reaction (PCR) (24-26) was carried out on a Bio-Rad T100 
thermo cycler. Hot Star Taq PLUS® Qiagen® reagents were used for PCR. In 
principle: the PCR master mix contained 1x reaction buffer including corral 
red loading dye, dNTPs (200 µM), Taq Polymerase (2.5 U/ µl), primers 
(200 nM  - 750 nM), additional magnesium if required (4 mM) and DNA 
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(10 ng/ µl) (for specific conditions see table PCR conditions). Reactions were 
carried out in volumes between 20 and 30 µl. PCR reactions were started with 
a heat activation of the polymerase at 95°C followed by 35 to 41 cycles 
consisting of an initial denaturation step at 95°C (30 sec), followed by 
annealing step (48-65°C, (30 sec) and finalised by an elongation step at 72°C 
(10 to 30 sec). The reaction was completed by a final elongation step for 
10 minutes at 72°C. The PCR product was thereafter stored at 4°C. For PCR 
reactions used for pyrosequencing, DNA treated by bisulfite conversion was 
used as a template. A first PCR consisted of a 5’ biotinylated primer and a 
non-modified primer on the counterstrand. For detailed PCR characteristics 
see Table PCR. 
5.6.9 Gel electrophoresis 
PCR products were separated in an electric field in 1 % agarose / 1 % TEA 
buffer gels containing SYBR green (188, 189) SYBR® safe DMSO stock 
diluted 1:10,000 for DNA labelling and visualised in ultra violet light in a 
BioRad Gel Doc™ reader.   
5.6.10 Quantitative PCR 
cDNA generated by reverse transcription as described (3 µl per reaction) was 
mixed with 15 µl of Q-PCR reaction mix containing primers at following 
SFRP2 (900 nmol), ADAMTS12 (375 nmol) and PITX2 (225 nmol) onto a 96 
well plate. The plate was centrifuged for 60 sec at 1000 x G in order to avoid 
air bubbles at the bottom of the wells. Quantitative PCR (qPCR) was carried 
out on a 7500 Fast Real-Time PCR system from Life Technologies . 
Reactions were set up as follows: initial activation of the primer at 90°C for 
10 min, followed by 45 cycles of 15 sec denaturation at 95°C and 60 sec 
annealing and elongation/detection at 60°C. As internal “house keeping” 
reporters beta-actin or TATA-box binding protein (TBP) were used.  For data 
interpretations ΔCT values (value reference gene – value target gene) were 
assessed and duplicates averaged. ΔΔCT values were calculated as the 
average of ΔCT of the reference sample minus the average ΔCT of target 




Pyrosequencing (191, 192) was performed using the Qiagen Pyrosequencer 
and related products according to the manufacturer’s instructions. Primers for 
amplicons up to 200 base pairs for pryosequencing (see PCR) were designed 
using Qiagen Pyrodesign software. Detailed list of primer sets are listed in 
table 2. PCR products (25 µl) were incubated together with 50 µl of binding 
buffer, 2 µl of avidin coated sepharose beads and 23 µl water for 10 to 20 min 
in round bottom 96 well plates on a shaker at 350 rpm in order to allow the 
biotinylated DNA strands to bind to the beads. Beads were then washed 
using the Pyrosequencing wash manifold firstly with 70 % ethanol for 10 sec 
in order to remove unbound DNA, followed by a 20 sec denaturation step in 
0.2 M NaOH followed by neutralisation in wash buffer (10 mM Tris-acetate pH 
7.6 and 4 M glacial acetic acid) for 10 sec. The beads were then transferred 
to 96 well reaction plates containing 43 µl annealing buffer and 1.5 µl 
sequencing primer (10 pmol/ µl working dilution). Samples were denatured for 
2 min at 80°C and thereafter cooled to room temperature on the benchtop. 
The plate was then mounted in the Pyrosequencer® with sample positions 
defined in the pyrosequencing software. The nucleotide injection sequence 
was determined using the pyromark setup program. The amount of 
nucleotides, enzyme mix (polymerase, ATP sulfurylase, luciferase, apyrase) 
as well as the substrate mix (adenosine 5’phosphosulfate, luciferin) was 
added into the disperser cartridge and added into the machine. After the run 
individual CpG methylation percentages were read and exported into a table 
for further processing in Excel and Prism and then plotted on the graph. The 
individual CpG sites in matching CAM and ATM were compared and 
semiquantitatively classified as gain or decrease in methylation.  





5.6.12 Dideoxy (Sanger) sequencing 
Verification of plasmid sequences: Isolated plasmids were sequenced by 
dideoxy sequencing (27, 193). On all three constructs the primer VP1.5 (5' 
GGACTTTCCAAAATGTCG 3'), Tm 49°C and XL39 (5' 
ATTAGGACAAGGCTGGTGGG 3') Tm 58°C were used for sequencing. The 
sequencing PCRs were carried out in a volume of 10 µl containing 
1x BigDye®, 1x Sequencing buffer, sequencing primer (0.06pM) and 500 ng 
of plasmid DNA. The reaction was started with a 60 sec denaturation step at 
96°C, followed by 27 cycles of denaturation for 20 sec at 95°C, annealing 
primer dependent (see table ) during 10 sec and a elongation at 60°C during 
4min. The reaction was completed by a terminal elongation step of 4 min at 
65°C. 
5.6.13 Purification of amplification product 
The amplification product of the sequencing PCR was purified using the 
CENTRI–SEPTM well strip columns. 
In brief, after a rinsing spin of the columns for 2 min at 750 x G the 
sequencing PCR product was loaded onto the gel columns and then cleaned 
through the separation matrix by another centrifugation over 2min at 750G. 
The eluate was thereafter vacuum dried in a vacuum bell and resuspended in 
5 µl of formamide. The sequencing process was carried out on an 
AbiPrism3100 capillary electrophoresis machine. Electropherograms were 
read on 4Peaks 1.8 software and aligned with digital sequence templates in 
Ape 1.17 and SnapGene® Viewer 2.7.3 software. 
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5.7 Methylation Array 
Methylation was measured using the Illumina Infinium HumanMethylation450 
BeadChip which allows to interrogate more than 485,000 methylation sites 
per sample at single-nucleotide resolution. Data was analysed using the 
Bioconductor package RnBeads (194). Differential methylation of various 
regions including sites, genes, promoters, CpG islands were calculated 
separately. Differentially methylated genes were identified using linear models 
and empirical Bayes algorithm and selected using the FDR corrected p-value 
cutoff of <0.05 and delta-beta >0.2. Data analysis was performed by 
Dr Jithesh Puthen, University of Liverpool. 
5.8 Expression Array 
Gene expression was measured using the Illumina HumanHT-12 v4 
Expression BeadChip which targets more than 47,000 probes and provides 
genome-wide transcriptional coverage of well-characterized genes, gene 
candidates, and splice variants. Bioconductor package lumi (195) was used 
for preprocessing the array data and limma (196) for differential expression 
analysis. Background correction, variance stabilizing transformation and 
Robust Spline Normalisation (RSN) were performed as part of the 
preprocessing. Differentially expressed genes were identified by linear 
models and empirical Bayes approach and a list of genes selected using cut-
off of FDR corrected p-value < 0.05 and fold change > |2|. 
5.9 Statistics 
Data analysis were done with Prism©. The final results were calculated as 
mean ± standard error of means (SEM) or as medians where appropriate. 
Student t-test, one-way and two-way ANOVA and correlation analysis were 
performed on the data as appropriate. Results were regarded as statistically 




6 Animals, Cells and Materials 
6.1 Animals 
Athymic Balb/C nu/nu mice (BALB/c-Nude Mice CAnN.Cg-Foxn1nu/ 
Crl  JAXTM) Mice Strain: CByJ.Cg-Foxn1nu/J were purchased from Charles 
River Laboratories, Manston Road, Margate, Kent CT9 4LT, United Kingdom. 
6.2 Tissue culture 
6.2.1 Cell lines 
Human oesophageal myofibroblasts from cancer patients (173/1,2&5, 
193/1&2, 282/1&2, 306/1&2, 360/1&2, 373/1&2, 467/1&2) were obtain from 
the University of Szeget, Hungary (table 3). 
 
Table 3: Cancer patients characteristics 
 
Normal tissue myofibroblasts (241/6, 246/6, 261/6, 279/6, 334/6, 351/6, 
474/6) were obtained from the University of Szeget, Hungary (table 4).  
Table 4: Control subjects characteristics 
 
Oesophageal cancer cells (OE19, OE21, OE33) (164) were purchased from 
the American type culture collection, ATCC, VA, USA. 
Human Umbilical Vein Endothelial Cells (HUVEC) were purchased from 
Lonza (Cambridge, UK). 
 
 53 
Cell labelling: PKH26 Fluorescent (red) and PKH67 Fluorescent (green) Cell 
Linker Kits ( Sigma-Aldrich, Gillingham, UK) 
Matrigel: Geltrex™ LDEV-Free Reduced Growth Factor Basement Membrane 
Matrix (Gibco™, no A1413202) 
Omeprazole (Sigma-Aldrich, Gillingham, UK; O104-500MG) 
5-Aza-2’-deoxzcztidine (Sigma-Aldrich, Gillingham, UK; No. A3656) 
6.2.2 Consumables 
Tissue culture flasks: TTP 75 cm2 and 25 cm2 (SLS TPP Flask 270 ml 75cm2 
60 ml 25 cm2 filtered, catalogue number: TIS7016 and TIS7012). 
Boyden chamber inserts: BD® Biocoat™ Corning™ with 8 µm pores 
(Systemic Laboratory Supplies, No. 354578).  
Tissue culture plates (6, 12, 24 well plates); Fisher Scientific, Nos. 10119831, 
10098870, 10604903). 
6.2.3 Cell culture media and solutions 
DMEM: Dulbecco’s Modified Eagle’s Medium - high glucose with 4500 mg/L 
glucose, L-glutamine, and sodium bicarbonate, without sodium pyruvate, 
liquid, sterile-filtered, suitable for cell culture, Sigma-Aldrich, Gillingham, UK; 
No. D5796. 
Antibiotic/antimycotic Solution (Sigma-Aldrich, Gillingham, UK; A5955). 
Penicillin/streptomycin (Sigma-Aldrich, Gillingham, UK; P0781). 
Non-essential amino acids (MEM Non Essential Amino Acids (100X), Life 
Technologies, Catalogue number: 11140035). 
Phosphate buffered saline (PBS) PBS (10x) PH7.4 W/O CAMG USA 
PLASTIC, Life Technologies, No 70011036. 
RecoveryTM cell freezing medium Invitrogen (GIBCO®) No 12648-010. 
Fetal bovine serum (FBS) was purchased from Lonza(DE14-802F). 
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Trypsin (0.25 % w/v)-EDTA solution: Trypsin Solution (0.5 g/l porcine trypsin 
and 0.2 g/l EDTA•4Na in Hank's Balanced Salt Solution with phenol red, 
Sigma-Aldrich, Gillingham, UK;  T3924). 
Matrigel (Corning, Tewksbury, MA, USA). 
Collagen-I (Millipore, Watford, Hertfordshire, UK). 
Ibidi® silicon two chamber inserts (Thistle Scientific Ltd, Glasgow, UK; No. 
80209). 
Click-iT® EdU Alexa Fluor® 488 & 594 Imaging Kit (Life Technologies, No. 
C10337 & C10639). 
 
Endothelial Growth media (EGM), Lonza Transfection kits, Amaxa™. 
PKH67 membrane labelling (Sigma-Aldrich, Gillingham, UK; PKH26GL).  
Lysogeny broth (LB) medium (500ml): Yeast extract BP1422-500 (1g), 
Tryptone microbial media 1279-7099 (2g), Sodium Chloride (2g). 
Agar for bacteria (500ml): Agar-Agar A/1080/53 (7.5g), Yeast extract 




Amaxa™ Fibroblasts Nucleofector™ kit and AmaxaTM Human MSC 
Nucleofector®, Lonza (VPD-1001). 
6.2.4.2 Prokaryotes: 
NEB Turbo Competent E. coli (High Efficiency), NEW ENGLAND BioLabs 
catalogue number C2984). 
6.2.5 Plasmids and siRNA 
Plasmids for overexpression of ADAMTS12, PITX2 and SFRP2 were 
purchased from Cambridge Bioscience (table 5) Lyophilised MISSION® 
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esiRNA esiRNA targeting human ADAMTS12, PITX2 and SFRP2 were 
purcheased from Sigma-Aldrich Company Ltd and resuspended in RNAse 
free water to a concentration of 1 µg/ µl (table 6).  
 










6.3 Nucleic acid extraction and handling 
6.3.1 RNA 
• miRNeasy mini Kit (50) (Qiagen, No. 217004). 
• RNase-Free DNase Set (50) (Qiagen, No. 79254). 
• Agilent RNA 6000 Nano Kit (Agilent Technologies, No 5067-151). 
• Agilent 2100 Bioanalyzer. 
6.3.2 DNA 
• QIAamp DNA mini Kit (50) (Qiagen, No. 51304). 
• Bisulfite conversion: EZ DNA Methylation-Gold™ Kit, ZYMO RESEARCH, 
No D5005 & D5006. 
6.3.3 Plasmids 
• Plasmid miniprep Kit: Zyppy™ Plasmid miniprep Dit (Zymo Research, 
No. D4020). 
• Plasmid Maxi Prep: Zyppy ™ Plasmid Maxiprep Kit (Zymo Research, 
No. D4028). 
6.4 PCR reagents 
AmpliTaq Gold (Thermo Fisher Scientific, Paisley, UK). 
PyroMark Gold (Qiagen Ltd, Manchester, UK). 
Taq DNA Polymerase (1000 U) 201205 (Qiagen Ltd, Manchester, UK). 
Centri-Sep™ spin colums (Applied Biosystems, No 401763). 
QPCR primers (ADAMTS12 Hs00229594, PITX2 Hs04183413, SFRP2 
Hs00293258) Life Technologies, Pailsey, UK) 
6.5 Reverse transcription 
High-Capacity RNA-to-cDNA™ Kit (Life Technologies, No. 4387406) 
6.6 Agarose Gel Electrophoresis 
High grade agarose (Sigma-Aldrich, Gillingham, UK) 
SYBR® Safe DNA Gel Stain (Life Technologies, Paisley, UK; No. S33110) 
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6.7 Staining & labelling 
Hematoxylin: Hematoxylin Solution, Harris Modified (Sigma-Aldrich, 
Gillingham, UK; No. HHS32). 
Eosinophil: Eosinophil Y solution (Sigma-Aldrich, Gillingham, UK; No. 
HT110232). 
Mounting medium: DPX Mountant for histology (Fluka BioChemika, No. 
44581). 
FISH Probe: Ready-to-use Human Chromosome Pan-Centromeric paints; 
FITC (Cambio, Cambridge, UK; 1695-F-01). 
Cover slips 22x50mm (Fisher Scientific, Loughborough, UK; No. 12333128). 
Microscope slides, Super frost, (3 x 1 inch) (Fisher Scientific, Loughborough, 
UK; No. 10149870). 
6.8 Solutions and Buffers 
20 x Sodium chlorid Sodium Citrate buffer (SSC): In 450ml deionized 
water 87.6g sodium chloride and  44.1g sodium citrate were dissolved, the pH 
adjusted to 7.0 and then more water upped to 500 ml. The buffer was then 
autoclaved and stored at 4°C. 
TE buffer: 0.01 M Tris, 0.1 mM EDTA, pH 7.5. 
PBT:  1 x PBS, 5 % protease free Bovine serum albumin (BSA) and 0.5 % 
Triton-X. 
TBS:  Tris-buffered saline: 50 mM Tris, 150 mM NaCl, pH adjusted to 7.6 with 
100 mM HCl. 
HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) 100 mM stock 
solution: 1.19 g in 40 ml of water, pH adjusted to 7.5, topped up with water to 








Epigenetic modification is a well-established event in carcinogenesis that 
affects not only the malignant cancer cells but also non-malignant stromal 
cells in the tumour microenvironment. Altered global DNA methylation is a 
hallmark of cancer cells characterised by a decrease of overall methylation 
compared to normal cells (106). A decrease of global DNA methylation has 
also been documented in CAMs accompanied by altered gene regulation 
(108, 113, 197).  
DNA methylation during replication is maintained by DNMT1 and DNMT3 
which can be inhibited with cytosine analogues such as DAC (49). Cytosine 
analogues have been well-established drugs in anticancer therapy since the 
late 1990s (198). The doses of DAC used to induce altered expression in vitro 
vary in the literature and direct mutagenic effects and induction of 
senescence upon DAC treatment have been documented. The effect of 
cytosine analogues on stromal cells has previously been addressed using 
immortalised fibroblast cell lines (113) and primary cell lines in mice (114) and 
humans  (110); moreover the effect of DAC on the overall DNA methylation 
has been assessed in immortalised fibroblasts (197). However, there have 
been no studies in primary myofibroblasts. Thus, while there is a wealth of 
work on the biological effects of DAC on malignant cells, little is known about 
these effects on non-malignant stromal cells.  
More generally, the effect of cytosine analogues on stromal cells of the 
oesophagus has not yet been investigated to the best of our knowledge. 
Generally, little is known of the implications of systemic treatment with 
cytosine analogues (199). The present study considered whether global DNA 
methylation differs between CAMs and ATMs of oesophageal cancer patients 
using pyro sequencing of LINE1 elements as a surrogate for global DNA 
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methylation. We also tried to establish a model of epigenetic modification of 
myofibroblasts using DAC 
 
7.1.1 Objectives 
The specific objectives were: 
• To assess whether there are differences in global methylation between 
CAMs and ATMs. 
• To assess whether epigenetic changes in primary myofibroblasts were 
induced by DAC.  
• To characterise the biology of myofibroblasts after DAC treatment in 
vitro and in vivo as a model for epigenetic modification of stromal cells. 
7.2 Material and Methods 
Myofibroblasts (241/6 and 261/6) were expanded in MM and treated with 
DAC as described (5.2.10). Cell expansion was assessed as described 
(5.2.7). 
Cell proliferation was assessed by EdU incorporation as described (5.2.6). 
Contractibility of myofibroblasts was assessed with gel contraction assays as 
described (5.2.8) using DAC treated myofibroblasts pelleted and resuspended 
in 2 ml of Matrigel.  
Transwell migration assays of myofibroblasts were performed as described 
(5.2.4). Migration was documented by photomicroscopy (5 images per 
chamber insert) and images processed to sequential time lapse videos as 
described (5.5.8).  
Cellular DNA was harvested with Qiagen DNeasy kits and assessed for 
quality and quantity by spectrophotometry as described (5.6.2). Between 0.5 
and 1 µg of DNA were then bisulfite-converted using the EZ DNA methylation 
Gold™ kit from ZymoResearch as described by the manufacturer. DNA 
methylation standards were used as controls. DNA methylation was assessed 
by LINE1 pyrosequencing analysis as described (5.6.11).  
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Myofibroblasts were treated with 0.1 µM or 0.01 µM DAC and injected into the 
flank of Balb/c nude mice (100 µl per mouse) as described (5.4.2).  
7.3 Results 
7.3.1 Assessment of global DNA methylation in myofibroblasts 
Global DNA methylation was assessed by pyrosequencing of PCR amplified 
LINE1 elements (figure 5). In four patients (173, 282, 306 and 373) all of 
six CpG sites in LINE1 elements were hypomethylated in CAMs. In patient 
193, three CpG sites were hypomethylated, two unchanged and one 
hypermethylated while in patient 467 five out of six CpG sites were 
hypomethylated in CAMs and one unchanged. Only in patient 360 were all 
CpG sites hypermethylated in CAMs compared to ATMs. When the 
comparison was extended to NTMs there was a trend towards lower 
methylation in CAMs compared to NTMs, but without reaching statistical 
significance. Global methylation at all sites was significantly lower in the two 
oesophageal cancer cell lines that were investigated in parallel (figure 6). 
When comparing the difference of all six CpG sites in the LINE1 amplicon 
investigated by pyrosequencing, a significant net decrease of global DNA 
methylation was detected  (p=0.0008) (figure 7). 
 
Figure 5: CpG methylation in LINE1 elements varies between CAMs and 














































islands varies between CAMs (red) and ATMs (green). Corresponding CpG 
sites are connected.  
 
Figure 6: Global DNA methylation in NTMs is higher than in CAMs and 
ATMs. Percentage of methylation in LINE1 elements in six (A - F) individually 
amplified CpG sites in NTMs, ATMs and CAMs. Two oesophageal cancer cell 
lines OE19 and OE21 are included.  
 
















































Figure 7: Global DNA methylation in NTMs is higher than in CAMs and 
ATMs. Box and whisker (Tukey) plot of percentage change for each individual 
CpG island (1-6) and the mean of all sites (all) for dinucleotide methylation in 
all CAMs and ATMs. Statistical analysis: one-sample t-test for column means 
different to the hypothetical value ‘zero’ indicating no change in methylation: 
CpG1 p=0.085, CpG2 p=0.062 and for the entire dataset p=0.0008. 
 
7.3.2 Model for epigenetic modification of myofibroblasts 
In order to modify DNA methylation, myofibroblasts were treated with different 
concentrations of DAC ranging from 0.001 µM to 10 µM, and global DNA 
methylation assessed (figure 8). The most potent effect of DAC treatment was 
achieved at a concentration of 0.1 µM leading to a reduction of global 
methylation by 10 %. Prolonged exposure of myofibroblasts to DAC did not 
further decrease global DNA methylation. 
 
Figure 8: DAC decreases global DNA methylation in NTMs in a 
concentration-dependant manner. Percentage of average LINE1 
methylation, assessed by pyrosequencing, in NTMs treated on 3, 6 or 9 
consecutive days by different concentrations of DAC. 
 
In studies on the long-term effect of DAC treatment on myofibroblasts, DNA 
methylation was assessed by pyrosequencing of LINE1 one day before (day -
1), one day after (i.e. day 4), ten and 15 days after the initial treatment (i.e. 
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global DNA methylation directly after the initial treatment and a relative 
increase two weeks after the treatment (figure 9). 
 
Figure 9: DAC induces a transient decrease of global LINE1 methylation. 
Time course experiment assessing global methylation of NTMs by LINE1 
methylation in myofibroblasts one day before treatment (i.e. -1) and at days 4, 
14 and 19 after initial DAC treatment with three different concentrations of 
DAC (0.1, 1 and 10µM) on 3 consecutive days. Matching CpG sites are 
connected with a line.  
 
7.3.3 Effect of cancer cell conditioned medium on myofibroblasts 
proliferation 
In order to provide a baseline for studies of myofibroblasts proliferation, 
initially we examined the effect of OE21 and OE33 cancer cell conditioned 
medium (CM21 and CM33 respectively) on proliferation of serum starved 
myofibroblasts exposed for 24 h to CM21 and CM33. Treatment led to a 































Figure 10: Effect of conditioned medium on EdU incorporation in 
myofibroblasts. Myofibroblasts were exposed for 24 h to conditioned 
medium of OE33 and OE21 cancer cells and then incubated for 2.5 h with 
EdU. The percentage of myofibroblasts with EdU incorporation is shown. 
Statistically increased EdU incorporation in student’s t-test.   
 
7.3.4 Effect of DAC treatment on myofibroblasts proliferation 
DAC treatment of myofibroblasts for 3 days decreased EdU incorporation 
from 40 % in control cultures to less than 10 %. The inhibition was 
concentration-dependent at concentrations below 0.1 µM. Prolonged 
treatment for 6 or 9 days did not further influence EdU incorporation (figure 
11).  EdU incorporation remained decreased after 8 and 28 days of treatment 
(figure 12 A). When DAC-treated cells cultured for 28 days were exposed to 
CM from OE21 cells there was a trend towards increased EdU incorporation 
that reached statistical significance only at a concentration of 1 nM DAC 



























Figure 11: DAC inhibits myofibroblast proliferation in a concentration 
dependent manner. EdU incorporation assessed one day after 3, 6 and 9 




Figure 12: DAC treated myofibroblast exhibit decreased proliferation 
8 days and 28 days after treatment. A) EdU incorporation 8 days after 
treatment with a serial dilutions of DAC ranging 0.001µM to 1µM. B) EdU 
incorporation 28 days after treatment with serial dilutions of DAC ranging from 
0.001 µM to 1 µM. Cells additionally exposed to conditioned medium from 
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Cell expansion assays demonstrated a clear suppression of cell proliferation 
by DAC in a concentration-dependent manner (figure 13). Treatment of 
myofibroblasts over 3 or 6 days decreased cell proliferation over the following 
18 days in culture. Extended treatment for 6 days had a marginally stronger 
suppressive effect on cell expansion compared to cells treated on three 
consecutive days at doses of 1 and 0.1 µM DAC (figure 14). 
 
Figure 13: DAC decreases NTM expansion on glass. Haematoxylin and 
eosin (H&E) stained sets of four glass cover slips containing NTMs 3, 6 and 
10 days after treatment with different concentrations of DAC. Note cell growth 
at 10 days returns after treatment with low concentrations of DAC. 
 
 
Figure 14: DAC decreases NTM expansion in a concentration-
dependant manner. H&E stained glass cover slips containing NTMs 18 days 
after 3 or 6 days treatment with different doses of DAC. Note that 1nM DAC 




7.3.5 Effect of DAC treatment on myofibroblast migration 
Basal migration of myofibroblasts in Boyden chamber assays is relatively low, 
and so to examine the effect of DAC treatment on migration the responses to 
a chemotactic stimulus were examined. Thus when the effect of CM from 
OE21 cells on transwell migration of normal myofibroblasts (261/6) and a pair 
of OESCC associated myofibroblasts (373/1,/2) was assessed, CM had a 
strong pro-migratory effect on the myofibroblast lines. The stimulated 
migration was higher in ATMs compared to matched CAMs (figure 15). 
Myofibroblast migration in Boyden chambers was increased in a 
concentration-dependent manner and persisted 7 days and 28 days after 
DAC treatment (figure 16 A). When cells kept in culture over 28 days were 
exposed to full medium or CM (OE21) transwell migration was increased 
(figure 16 B). 
 
Figure 15: Cancer CM stimulates myofibroblast migration. Conditioned 
medium from OE21 cancer cells stimulates NTM (261/6), ATM (373/2) and 
CAM (373/1) migration in Boyden chamber assays. Mean increase of 
migration between serum-free control conditions (-) and OE21 conditioned 
medium (CM OE21) is 5.8x for NTM, 14.7x for ATM and 7.1x for CAM. 
Asterisks indicate statistical significance in t-test.  
 
In order to study the effect of DAC treatment on myofibroblast migration, 
















migration was assessed. These assays demonstrated an increased migration 
of myofibroblasts upon DAC treatment (16).  
 
Figure 16: DAC persistently increases myofibroblast migration. Boyden 
chamber transwell migration of 241/6 NTMs seven days (A) and 28 days (B) 
after DAC treatment. NTMs display a higher migration rate 28 days after DAC 
treatment when exposed to conditioned medium form OE21 cancer cells (B). 
Statistical significance p between groups with student’s t-test. 
 
The effect of DAC treatment on migration towards OE21 cells was also 
investigated with the use of the ibidi® chamber system. Myofibroblasts 
treated with DAC (0.1 µM) not only exhibited increased migration towards 
cancer cells, but there was also increased cancer cell migration towards 
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Figure 17: Ibidi migration assay. A) photomicrograph at 25 h after co-
culture. B) percentage of closure of area between cells at 25 h. Red for area 
between DAC treated myofibroblasts and OE21 cancer cells, green for area 
between mock treated myofibroblasts and OE21 cancer cells. Error bars 




Figure 18: DAC treatment of myofibroblasts bidirectionally increases 
migration of myofibroblasts and cancer cells towards each other. A) 
photomicrograph of DAC treated myofibroblasts (upper) and sham treated 
myofibroblasts (lower) at time point 0 h and 18 h. OE21 cancer cells are on 
the left side, myofibroblasts on the right side in all cases. B) myofibroblast 
migration towards OE21 cells. Difference of growth area significant in two way 
ANOVA (p<0.0001) 
 
7.3.6 Effect of DAC on myofibroblast contractility 
Myofibroblasts treated with different concentrations of DAC exhibited changes 
in gel contraction used as a surrogate marker for cell contractility. Thus 
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treatment of myofibroblasts with 1 nM DAC led to a significant increase in gel 
contraction compared to mock-treated myofibroblasts (19). However, DAC at 
0.1 µM did not significantly affect gel contraction. Myofibroblasts treated with 
1 µM DAC exhibited a trend towards a reduced contractibility as compared to 
untreated controls.  
 
Figure 19: Gel contraction assay of NTM treated with DAC. A) gels in 24 
well plate after 6 hours of contraction using myofibroblasts treated with 
vehicle only and 0.001, 0.1 and 1 µM DAC. B) corresponding graph depicting 
percentage of contraction. Value for statistical significance as compared to 
vehicle control in t-test p=0.02.  
 
7.3.7 DAC treated myofibroblasts have no significant effect on OE21 
cell proliferation 
The effect of conditioned medium collected from DAC treated myofibroblasts 
(CMDAC) on OE21 proliferation was not significantly different from that of 
conditioned medium from untreated cells (CMCTL) (figure 20). In co-culture 
experiments, the ratio of NTM to OE21 cells affected the proliferation rate of 
the latter: OE21 proliferation was lower when the ratio of NTM towards OE21 
was 1:1 as compared to the condition in which OE21 cell outnumbered NTM 
by a ratio of 2:1  (figure 21). When NTMs were pre-treated with DAC the 
proliferation rate of co-cultured OE21 cells was slightly decreased (mean 
proliferation 30.5 % vs. 32.3 %) and (24.5 % vs. 28 %). However, the 
differences in OE21 proliferation did not reach statistical significance (p=0.61 
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and p=0.24 respectively); the proliferation in myofibroblasts was not affected 
by the ratio of OE21 cells and NTMs (not shown).  
 
Figure 20: Effect of DAC treated NTMs on OE21 cell proliferation 
(conditioned medium and co-cultures. A) representative photomicrographs 
(100x) of pan cytokeratin (red), alpha-SMA (green) and nuclei with EdU 
incorporation (green). Top row: OE21 cells incubated 24h in conditioned 
medium (CM) from DAC pre-treated NTM and untreated NTMs (CTL), in 
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serum free medium. Lower row depicts co-cultures of OE21 cancer cells and 
either DAC pre-treated NTMs (left) or untreated NTMs (white arrows indicate 
proliferating OE21 cells, green arrows proliferating NTMs). B): A-C: OE21 cell 
proliferation after 24h incubation in CM of A, serum free medium; B, NTM CM; 
and C, DAC  treated NTM (NTMDAC). C) D: 1:2 ratio of NTMs co-cultured with 
OE21 cells; E: 1:2 ratio of NTMDAC co-cultured with OE21 cells; F, 1:1 ratio of 
NTMs co-cultured with OE21 cells; G, 1:1 ratio of NTMDAC co-cultured with 
OE21 cells. No statistically significant difference between mock treated and 
DAC treated groups.  
 
 
Figure 21: DAC treated myofibroblasts and their conditioned media 
decrease OE21 cell proliferation. Relationship between OE21 cells per field 
(X-axis) and percentage of proliferating OE21 cells per field (Y-axis). Top row: 
50,000 OE21 cancer cells exposed 24h to conditioned medium from DAC 
treated, control treated and serum-free medium. Row A) ratio of plated NTM 
to OE21 cells 1:2; row B) ratio of plated NTM to OE21 cells 1:1 
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7.3.8 Conditioned media from DAC treated myofibroblasts accelerate 
OE21 migration  
Conditioned medium harvested from DAC treated myofibroblasts increased 
OE21 migration in a transwell migration assay (figure 21). 
 
Figure 21: Conditioned media from DAC treated myofibroblasts 
increases OE21 cell migration. Assessment of OE21 cancer cell migration 
towards conditioned medium from vehicle (black) or DAC (red) treated NTM. 
Statistical significance in t-test, p<0.0001. 
 
7.3.9 DAC treated myofibroblasts accelerate OE21 invasion in a 3D 
assay.  


































Figure 22: DAC treated myofibroblasts accelerate OE21 invasion in a 3D 
assay. Invasion of OE21 cancer cells into underlying matrigel containing 
untreated myofibroblasts (OE21 + NTM) and DAC treated myofibroblasts 
(OE21 + NTM (DAC)). A) representative photomicrographs, B) average depth 
of invasion on the right +/- SEM, p=0.009 (student t-test).   
 
7.3.10 Influence of DAC treated myofibroblasts on xenograft tumour 
growth 
In mouse xenografts, DAC treated myofibroblasts injected together with OE21 
cancer cells significantly accelerated tumour growth (figure 23). Histologically 
there was no gross difference between end stage tumours of xenografts 
containing DAC- or sham-treated myofibroblasts. 
 
Figure 23: DAC treated myofibroblasts stimulate tumour growth in an 
oesophageal cancer xenograft model. Statistical significance for increased 
tumour size at day 32 p=0.045 and p<0.0001 at day 37 for xenografts with 
myofibroblasts treated with 0.1µM DAC and p=0.0008 at day 37 for 
myofibroblasts treated with 0.001µM DAC. Statistical significance in 2-way 
ANOVA.  
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Altered global DNA methylation is a key feature of malignant cells. In 
particular, methylation of gene promoters regulates transcription (200). In 
malignant tumours altered gene promoter methylation is frequently observed 
in tumour suppressor genes such as PTEN (201), MLH1 in colorectal (202) 
and endometrial cancer (203, 204) and CDKN2/p16INKa4 in various tumours 
but also in Barrett’s oesophagus (205). For many tumours it is known that 
altered gene expression due to promoter methylation is of predictive value (as 
for example MGMT in glioblastoma multiforme, MLH1 in colorectal and gastric 
cancer (206, 207)). In vitro and in vivo modification of promoter methylation in 
cancer cells has been targeted in order to reactivate epigenetically silenced 
tumour suppressor genes (208). Furthermore cancer cells typically show a 
decrease in their global DNA methylation (209) and in repetitive elements 
such as LINE1 and Alu (106).  
Different global DNA methylation levels between normal stroma and tumour 
adjacent stroma has been described for cancers of the stomach (109), non-
small cell lung cancer (108) and ductal adenocarcinoma of the pancreas 
(210). Whether DNA methylation differs between CAMs and ATMs in 
oesophageal tumours and the biological impact of chemically altered DNA 
methylation in oesophageal myofibroblasts has, to our knowledge, not yet 
been addressed. Indeed, in general little is known of the functional 
significance of epigenetic modification of stromal cells.  
We first assessed global DNA methylation in oesophageal myofibroblasts by 
analysing the DNA methylation of LINE1 elements. We found that CAMs 
show a relative global hypomethylation in comparison to ATMs. These 
findings stand in accordance with other data published by Jiang et al (109) on 
global DNA methylation of tumour associated myofibroblasts of the upper 
gastrointestinal tract. They showed in their work using a methylation-sensitive 
single nucleotide polymorphism array (MSNP), [3H]dCTP incorporation assay 
and an antibody approach that DNA methylation in gastric cancer 
myofibroblasts was decreased as compared to their tumour adjacent 
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counterpart. Jiang and his colleagues also observed a decrease of DNA 
methylation in precancerous/dysplastic epithelia and tumours of a transgenic 
gastric cancer-developing mouse model.  
In order to mimic a hypomethylated state in myofibroblasts we successfully 
established a model for a reduced global DNA methylation in NTM with the 
use of the demethylating chemotherapeutic DAC, as successfully shown by 
others in fibroblasts and cancer cells (113).  In previous studies, global DNA 
methylation in myofibroblasts had not been assessed on the basis of LINE1 
element methylation. Nevertheless, our results overlap with data obtained 
from HPLC analysis (113). Liang et al also observed in an expression array 
approach, that cells treated with a DNMT inhibitor exhibited persistently 
altered gene expression. This phenomenon was more prominent in cancer 
cell than in non-malignant stromal cells. I demonstrate here that 
myofibroblasts treated with DAC show an immediate but also long-term 
response, i.e. decreased proliferation, increased migration in two in vitro 
models (Boyden chamber assay and ibidi® chamber system), increased 
contractibility (gel contraction assay) and an accelerated tumour growth in 
vivo.  
At this stage, the aim of our study was not to investigate the molecular 
mechanisms responsible for the biological effects of altered methylation, but 
rather to assess whether functionally relevant epigenetic modification per se 
can be achieved in stromal cells. In a second step we wanted to evaluate 
whether the modified myofibroblasts could then be used as a model for 
epigenetic modification in vitro. The persistence of altered migration, 
contractility, proliferation and interaction with cancer cells upon treatment 
suggest that these changes are not cytotoxic effects of DAC but rather the 
result of altered DNA methylation which is passed onto daughter cells. We 
cannot, however, exclude the possibility that a portion of the cells exposed to 
DAC acquired germ line mutations or entered senescence. Nevertheless, the 
observed biological effects are best explained as consequence of loss of 
promoter methylation under the DAC treatment.  
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In order to elicit the most effective concentration of DAC for our purpose, i.e. 
altered DNA methylation and persistent viability of the cells, we performed 
dose response experiments for DNA methylation and proliferation. From data 
gained in studies on immortalised fibroblasts we knew, that DAC transiently 
reduces proliferation which recovers, but persistently modifies cell fate 
leading to a reduction of the cell doubling number (211).  
We have shown that conditioned medium from cancer cells increased 
myofibroblast migration in a transwell migration assay. This finding stands in 
agreement with a report that conditioned media from OESCC cells induced 
αSMA expression in fibroblasts (170). We did not assess whether αSMA 
expression was increased in NTMs exposed to CM from cancer cells, but the 
increased migration can be regarded the result of increased expression of 
proteins of the contractile apparatus.  
We were able to confirm that conditioned medium from cancer cells increased 
stromal cell (in our case myofibroblasts) proliferation. This phenomenon was 
consistent for OE21 squamous cell carcinoma and the OE33 Barrett’s 
carcinoma cell lines. This mitogenic effect of cancer cell conditioned medium 
was reduced when NTMs were treated beforehand with a DAC. This is an 
interesting finding, since we observed that the potential to increase 
proliferation in CAMs was markedly reduced upon cancer conditioned 
medium exposure as compared to matched ATMs. This further outlines the 
difference between CAMs and ATMs and shows that DAC treatment shifts 
NTMs closer to a CAM phenotype. Our findings are also comparable to the 
observation on altered behaviour of normal transformed keratinocytes and 
HaCaT cells which show increased proliferation and migration in scratch 
wound assay after exposure to conditioned medium from “nemotic” 
myofibroblasts (212-214). 
The tumour promoting ability of stromal cells is thought to be mediated via 
angiogenic, anti-apoptotic, immunosuppressive effects as well as extra 
cellular matrix production.  Whereas various chemotherapeutic approaches 
interfering with angiogenesis and immune response are currently in use, a 
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validated therapy against the tumourigenic effects of stromal cells is still 
lacking. The tumour stroma not only promotes tumour growth, but is also 
believed to prevent chemotherapeutic agents reaching their targets. The so 
called desmoplastic stromal reaction, a reactive hyperplasia of stromal cells 
to cancer cell stimulus is observed in various cancers and is particularly 
prominent in pancreatic ductal adenocarcinoma (PDAC)(215). In a model of a 
stroma-rich PDAC DAC treatment of myofibroblasts prior to co-injection with 
cancer cells into nude mice delayed tumour progression (210). Our data on 
the effect of DAC treated myofibroblasts in mice point in the opposite direction 
to the data of Shakya et al. Thus, in our hands DAC treated NTMs 
accelerated OE21 tumour growth while Shakya et al observed that 
pretreatment of murine PDCA derived CAFs reduced tumour growth. 
Interestingly, they reported persistent proliferation of CAFs at treatment doses 
of 2 µM DAC, whereas we observed that proliferation of myofibroblasts was 
suppressed at a dose of 0.1 µM DAC. This comparison has to be carried out 
with caution, since Shakya investigated murine CAFs derived from cancer 
producing transgenic mice in severe combined immunodeficiency (SCID) 
recipient mice whereas we used primary human myofibroblasts and 
oesophageal cancer cell lines in BALB/c nude mice. 
Our observation is that treatment of myofibroblasts with DAC in vitro 
persistently decreases proliferation comparable to “nemotic” myofibroblasts. 
The DAC induced CAM-like phenotype with a stimulating effect on migration 
and proliferation in cancer cells in vitro and the accelerated tumour growth 
in vivo indicates that epigenetic modulation of stromal cells may have an 
unexpected adverse effect on tumour outcome. The use of deacetylating 
drugs may contribute to the development synchronous and metachronous 
tumours. To date there are no data available on long term effects of 
demethylating agents in respect to secondary tumours.  
Conclusion 




• DAC induces a transient hypomethylation in NTMs and persistent 
biological effects.  
• DAC treatment of myofibroblasts can be used as a model for 
epigenetic cell modification 
• DAC treated myofibroblasts accelerate the growth of subcutaneous 
xenografts. 
 
8 Myofibroblasts promote tumour growth of 
oesophageal squamous cell and adenocarcinoma in 
xenografts 
8.1 Introduction 
Tumour stroma cells can be isolated by outgrowth methods in a form that is 
suitable for in vitro culture (216, 217). Importantly, cancer associated stromal 
cells have been reported to play an important role in the maintenance of a 
provisional tumour stroma (218). However, a comprehensive understanding 
of tumour biology also depends on the ability to study the interactions 
between the different cellular components. Various in vitro and in vivo models 
exist in order to address these questions and more elaborate models continue 
to be developed. Murine xenograft models have been employed since the late 
1960s (183) and are still widely used. It has been noted that when human 
stromal cells are injected together with cancer cells into recipient mice the 
stromal cells disappear (219). Even so, little is known of the fate of these cells 
and their role at early time points in xenografts. 
Data generated in our group show that myofibroblasts derived from gastric 
tumours promote tumour growth when injected together with MKN45 gastric 
cancer cells in immune compromised nude mice (97). Kandola also observed 
a tumour growth inhibitor effect of myofibroblasts on distant MKN45 reporter 
tumours (97). Myofibroblasts isolated from the tumour bulk have been shown 
to exert a stronger tumour growth promoting effect than matched 
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myofibroblasts isolated from adjacent tissue. Moreover, in Barrett’s 
adenocarcinomas CAFs have been associated with adverse outcome (84).  
Myofibroblasts promote cancer growth in vitro mimicking early tumour growth, 
but their role in early in-vivo models remains relatively unexplored. In order to 
address this question we established xenograft models for oesophageal 
cancer growth using an oesophageal squamous cell carcinoma cell line 
(OE21) and a Barrett’s adenocarcinoma cell line (OE33) (164) in combination 
with primary oesophageal myofibroblast lines, i.e. NTM, CAM and ATM 
generated and previously characterised by the group (table 3 & 4).  
In addition, we examined the possible role of gastrin in oesophageal 
adenocarcinoma xenografts. It had previously been shown that gastrin has 
complex actions both accelerating and inhibiting tumour cell growth in gastric 
adenocarcinoma cells expressing the cholecystokinin receptor (CCK) 2 (AGS-
GR) (184, 220) via ERK signalling (221). Kumar et al have shown that gastrin 
stimulates migration of AGS-GR cells in a MMP1 dependent manner (169, 
170). It remains unclear whether hypergastrinaemia accelerates tumour 
growth in vivo through CCK-2 receptor signalling pathway. We investigated 
whether CCK-2 receptor expression in a Barrett’s carcinoma cell line would 
also accelerate tumour growth and whether the latter was influenced by 
myofibroblasts with the use of the established xenograft models. 
8.2 Objectives 
The specific objectives were: 
• To establish mouse xenograft models in order to study the role of 
primary human oesophageal myofibroblasts on tumour growth. 
• To investigate the role and fate of primary human myofibroblasts in 
xenografts. 
• To study whether human myofibroblasts have a systemic effect on 
cancer growth. 
• To determine whether hypergastrinaemia accelerates tumour growth in 




8.3 Material and Methods 
For these experiments we used an established oesophageal squamous cell 
carcinoma cell line (OE21) and a Barrett’s adenocarcinoma cell line (OE33) 
(164) in combination with primary myofibroblast lines generated by the group 
in collaboration with the University of Szeget. The NTM line 241/6, which in 
our hands is typical NTM line, was also used. For CAMs, we used line 373/1 
and 467/1 which have been shown in previous work of the group (87, 95) to 
be a phenotypically typical CAMs and different from their matched ATMs.  
Single cell suspensions (cancer cells alone or in combination with 
myofibroblasts) were injected into nude mice. Tumour volumes were 
assessed on a regular basis and animals sacrificed at defined time points for 
histology as described (5.4.2).  
Fluorescence in situ hybridisation against human centromeres and immune 
fluorescence histology were performed on snap frozen tissue (5.4.4). 
Systemic hypergastrinaemia in mice was induced with omeprazole (5.4.3).  
8.4 Results 
8.4.1 Establishment of a mouse model for oesophageal Barrett’s 
carcinoma in combination with primary human myofibroblasts 
Initially I established the lowest number of cancer cells needed to form 
tumours in nude mice. Groups of nude mice (n = 3) were injected with 0.3x106, 
0.6x106 and 1.2x106 OE33 cancer cells alone or in combination with 3x105 
normal tissue myofibroblasts (NTM line 241/6). In the 0.3x106 group (figure 24 
A) one animal in the OE33 alone and two in the combined OE33/NTM group 
started to grow tumours with a latency of 45 days. In the 0.6x106 OE33 cell 
group (figure 24 B) all animals receiving NTMs developed prominent initial 
tumours significantly discriminating them from the OE33 cell only group. The 
tumour size difference peaked after 2 days (p<0.0005) of injection and slowly 
diminished over the following three weeks. Only one tumour in the combined 
group started to grow after 65 days, reaching 80mm3 after 74 days. In the 
1.2x106 OE33 cancer cell group (figure 24 C) again, all NTM containing 
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xenografts developed initial tumours significantly larger (p<0.005 at day 2) 
than their OE33 cancer cell alone counterparts. In both groups tumours 
started to grow after 42 days. Histologically there was no gross difference 
between the end stage xenografts (figure 24 D).  
 
Figure 24: Optimisation of Barrett’s cell carcinoma cell line (OE33) 
xenografts in nude mice. A) xenograft tumour volumes of  individual mice 
injected with 0.3x106 OE33 alone (pink) or co-injected with 0.3x106 NTMs 
(241/6: blue). B) 0.6x106 OE33 alone (pink) and co-injected with 0.3x106 
NTMs (blue). C) 1.2x106 OE33 alone (pink) and co-injected with 0.3x106 
NTMs (blue). Statistical significance *: p<0.05, **: p<0.005, ***: p<0.0001, 
repeated measure two-way ANOVA). D) No gross histological difference 
between tumours consisting of injected myofibroblasts and cancer cells.  
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8.4.2 Investigation of the early tumour formation in xenografts 
consisting of OE33 cancer cells and myofibroblasts 
In order to address the observation of an early tumour formation in mice when 
NTMs were co-injected with tumour cells, I injected 3 groups of mice (n = 4 
per group) with 6x105 OE33 cells alone, 3x105 NTM (241/6) alone or 6x105 
OE33 combined with 3x105 NTM (figure 25). There was a significantly 
increased tumour formation when NTM were injected together with OE33 
cells (p<0.0005) on day 1 and day 2 after injection. A similar effect was 
observed when I injected NTMs alone 1 day after injection (p<0.05) on day 1 
after injection. Animals were sacrificed after two days and the tumours 
histologically examined. In the OE33 alone group the cancer cells were 
dispersed as small groups of cells in oedematous and serous empty spaces, 
whereas in the combined OE33/NTM group the cancer cells were found 
surrounded by myofibroblasts and the latter seemed firmly attached to the 
adjacent murine host tissue (figure 25 B and D). When NTMs were injected 
alone, an early tumour formation was observed and the injected 
myofibroblasts were identifiable on H&E stained slides (figure 25 A and F, 
26 G). After 28 days these early tumours in NTM-only grafted mice 
macroscopically disappeared (figure 26 G) and were also not detectable on 




Figure 25. Myofibroblasts induce early stroma-type reaction in OE33 
cell xenografts by generating a niche for cancer cells. Day two 
xenografts of A) NTMs, B) OE33 cells combined with NTMs and C) OE33 
cells alone (100x magnification;. 400x magnification of combined OE33 and 
NTM day two xenografts); D) haematoxylin and eosin stain, black arrows 
indicate NTMs; E) immune FISH (anti pan-cytokeratin: red; anti-vimentin: 
green; pan-human centromere: white), red arrow head indicates OE33 cells, 
white arrow heads NTMs. F) Xenograft median tumour volumes; 6x105 
OE33+3x105 NTMs vs 6x105 OE33 p=0.0005; 6x105 OE33+3x105 NTMs vs 
3x105 NTMs p=0.0036; 6x105 OE33 vs 3x105 NTMs p=0.075 (repeated 
measure two way ANOVA)(* p<0.05, * p<0.001; Bonoferri post test vs OE33 
alone)  
 
8.4.3 Establishment of a mouse model for oesophageal squamous cell 
cancer with primary human myofibroblasts 
In the case of OE21 cells, I again established the lowest number of cancer 
cells needed to be injected in order to grow tumours in nude mice using 105, 
3x105 and 106 OE21 cancer cells alone or in combination with 3x105 normal 
tissue myofibroblasts in nude mice (n = 3 per group) (figure 26 A, B, C). In the 
1x105 group only one mouse grew a tumour. When 3x105 OE21 cells were 
injected, all animals grew tumours and tumour growth was significantly 
accelerated when NTMs were co-injected with the cancer cells (figure 26 B & 
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D). This growth advantage disappeared when 6x105 or more OE21 were 
injected (figure 26 C, E, F) even when the ratio of OE21 to cancer cells was 
kept constant (figure 26 E, F). When myofibroblasts alone were injected only 
a small tumour formation was observed soon after injection (figure 26 G). The 
initial tumour appeared in all groups in which myofibroblasts were injected but 
was present to a lesser extent when OE21 cells alone were injected. Tumour 
growth in the NTM containing xenografts was also increased when 5x105 
NTM were injected together with 106 OE21 cancer cells (figure 26 H). 5x105 
CAMs 373/1 had a stronger tumour promoting effect than when the same 
number of ATMs 373/2 were injected together with 106 OE21 cancer cells 





Figure 26. Optimisation of OE21 cancer cell number for xenografts. 
Xenograft tumour volumes; upper row optimisation of OE21 cancer cells; A) 
105 OE21 with or without 3x105 NTMs, individual tumours, B) 3x105 OE21 
with or without 3x105 NTMs, mean +/- SEM; p=0.062, and C) 10x105 OE21 
with or without 3x105 NTMs, mean +/- SEM. D) 3x105 OE21 with or without 
3x105 NTMs; p=0.0088; E) 6x105 OE21 with or without 3x105 NTMs, mean +/- 
SEM and F) 9x105 OE21 with or without 3x105 NTMs, mean +/- SEM, G) 
3x105 NTMs alone, individual animals. H) tumour volumes of OE21 cancer 
cells alone (black) and co-injected with NTMs (241/6) (red), p = 0.0043; I), 
OE21 cells co-injected with CAMs (373/1; red) and ATMs (373/2; purple) and 
OE21 cells co-injected with ATMs (blue). p < 0.001; two-way ANOVA. 
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Histologically there was no gross difference between the two xenograft 
groups when tumours reached maximal, ethically-approved, size (figure 27). 
In both groups pushing border but also infiltrating tumour borders were 
observed together with peri-tumoural fibrosis and mild chronic inflammatory 
infiltrate. 
 
Figure 27 A): Representative photomicrographs of end stage tumours 
of xenografts. Xenografts consistent of A) OE21 + 373/1 (CAMs), B) OE21 + 
373/2 (ATMs) and C) OE21 alone; scale bar 500 µm.  
 
8.4.4 The role of co-injection of myofibroblasts in early xenografts 
The phenomenon of early tumour formation and the fate of myofibroblasts 
was then examined in a time course experiment in which those animals with 
the largest tumours on days 2, 7 and 28 were sacrificed for histology (figure 
28). The groups consisted of OE21 cells alone (figure 28 A), OE21 cells 
together with CAMs (373/1) (figure 28 B), OE21 together with NTMs (241/6)  
(figure 28 C) and OE21 cells together with PKH26 labelled NTMs (figure 28 
D). The average tumour diameters in the groups containing CAM or NTM 
were significantly larger at day 2, 7 and 28 compared to the OE21 cancer cell 




Figure 28: Time course of individual oesophageal squamous cell 
carcinoma xenograft growth. A - D) xenograft volumes after injection. 
Interceptions indicate time points when the animals with the largest tumours 
in each group were taken for analysis (day 2, 7 and 28). A) 3x105 OE21 cells 
alone or co-injected with 3x105 myofibroblasts: 373/1 CAMs in B), 241/6 
NTMs in C) and PKH26 labelled 241/6 NTMs in D). Statistically significant 
difference in tumour size at day 2  (E), 7 (F) and 28 (G) after xenografting in t-
test. * for p<0.05, ** for p<0.01, *** for p<0.001 and **** for p<0.0001. 
 
Two days after injection tumours showed a significantly increased 


















































































































































































































myofibroblastic cells in mixed OE21 + CAM or NTM tumours. The extent of 
necrosis at day two was more prominent in the OE21 + CAM group. Day 
seven tumours showed an increased inflammation, more prominent necrosis 
and persistence of myofibroblastic cells in the OE21 + CAM group. 
Keratinisation of cancer cells was more prominent in the OE21 + NTM group. 
The variance between tumours of independent xenograft experiments (28 
days and 2 month tumours) was little (figure 29). 
 
 
Figure 29: Histology of early xenografts. Upper panel: representative 
photomicrographs of tumours at day 2 (A-C) and 7 days (E-F) after xenograft 
injection. A & D OE21 cells alone, B & E OE21 cells + CAMs, C & F OE21 
cells + NTMs. Scale bar 200 µm. Lower panel semi quantitative histological 
scoring of tumours after 2, 7, 28 days and 2 month for inflammation, 




















































































































































with activated myofibroblastic features. Statistical significance in two-way 
ANOVA p<0.05 marked with asterisk.  
 
8.4.5 Fate of co-injected myofibroblasts in oesophageal OE21 and 
OE33 xenografts 
In order to study the fate of myofibroblasts injected into xenografts we 
labelled NTMs prior to injection with PKH26 a membrane-integrating dye. 
Already seven days after injection the dye was detectable in cells other than 
myofibroblasts (figure 30). The fluorescence intensity of the dye breached 
through different filters and diagnostic IF could not be produced. At late 
tumour stages, fluorescence was only detected focally in stromal cells and 












Figure 30: fluorescent microscopy pictures of xenografts. Upper panel 
representative image of PKH-labelled tumours at day 7. 
Photomicrographs of mixed myofibroblasts/OE21 cancer cells 7 days after 
injection. The tumour depicted in the upper row (A) contains unlabelled 
myofibroblasts, whereas the tumour in the lower row (B) contains PKH26 
labelled myofibroblasts. 1: nuclear stain with DAPI, 2: Pan cytokeratin (FITC), 
3: PKH26 (red spectrum filter). Lower panel I-FISH of xenografts: human 
myofibroblasts disappear in xenografts between 1 week and 4 weeks after 
injection. I-FISH of xenografts consisting of myfibroblasts and OE21 cancer 
cells. Upper row, low power magnification; lower row, high power 
magnification of combined xenografts 2, 7 and 28 days after injection. Pseudo 
colours: pan-cytokeratin: red, DAPI: blue, human centromeres: white. 
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To further define cells of human origin in mice hosts, we employed FISH 
using a human pan-centromeric probe. The probe displayed 100 % positivity 
in human primary myofibroblasts and OE21 cancer cells. A positive signal 
was never detected in murine tissues. When human centromere FISH was 
performed on tumours derived from animals with PKH26 labelled 
myofibroblasts a nuclear localisation of the FISH signal was not detected in 
PKH26 positive stromal cells (n=3 mice; 28, 54 and 56 days after xenograft 
injection). Immunofluorescence plus in situ hybridisation (I-FISH)-labelled 
cancer cells were identifiable by their epithelial characteristic pan-cytokeratin 
immunoreactivity. I-FISH performed on early tumours (figure 30) consisting of 
OE21 or OE33 combined with myofibroblasts (day 2 and day 7) revealed 
FISH positive cells with nuclear features of myofibroblasts in between FISH 
and CK positive cancer cells (n=6). FISH positive nuclei in stromal cells of 
tumours aged 28d or older were never identified (n=14). Furthermore when I-
FISH was performed combining pan-cytokeratin with an anti-murine 
centromere probe, all stromal cells but not the cytokeratin positive cells were 
FISH positive (figure not shown). 
 
 
8.4.6 CAM cell line 467/1 accelerate distant tumour growth 
In order to study whether myofibroblasts might exert a systemic effect on 
tumour growth, animals were injected on one side with cancer cells and 
myofibroblasts and on the other side with a “reporter” tumour consisting of 
cancer cells only. Tumour volumes were measured on both sides (figure 31). 
When CAMs (467/1) were injected together with OE21 in one flank, the 
contralateral OE21-only tumours showed a significantly increased tumour 
growth (C) as compared to tumours where no myofibroblasts were injected 
(B). When NTMDAC (see figure 3) were injected together with OE21 cells no 
difference regarding contralateral tumour growth was observed as compared 




Figure 31: CAMs 467/1 systemically stimulates tumour growth. Animals 
(groups of six) were injected bilaterally with tumours consisting on one side of 
OE21 cells and myofibroblasts and on the contralateral side with OE21 cells 
only. Figure A depicts contralateral tumour growth. Statistical significance 
p<0.001. B-E individual bilateral tumour growth on the myofibroblast bearing 
side (in colours) upwards, for the indicator tumours (in gray) downwards. 
 
8.4.7 Effect of gastrin on growth of Barrett’s carcinoma xenografts 
In order to study the influence of elevated systemic gastrin concentrations on 
Barrett’s carcinoma growth we used a Barrett’s carcinoma cell line (OE33) 
overexpressing CCK-2R (OE33-GR). Hypergastrinaemia was induced by 
treating mice with omeprazole (400 µmol.kg-1), a proton pump inhibitor, three 
times per week, starting one week prior to xenograft injections. The 
experiment included four groups of six animals either bearing tumours 
consisting of OE33-GR only or OE33-GR and myofibroblasts with or without 
omeprazole induced hypergastrinaemia. On the first two days after injection 
there was a significant tumour size difference between myofibroblasts-
containing tumours and cancer cell-only tumours (p<0.001). There was no 
difference between the omeprazole treated and the untreated group during 
the first few days. Accelerated tumour growth was observed in two animals on 















































































































omeprazole in which OE33-GR cells were injected together with 
myofibroblasts (figure 32). All other xenografts were stagnant or disappeared 
(2 omeprazole treated tumours) within 2.5 months. When comparing all 
omeprazole treated xenografts excluding the two animals with accelerated 
tumour growth to all tumours in the mock treated animals the mean tumour 
volume was significantly lower on days 3, 4, 20, 30, 39, 46 and 51-70 in the 
omeprazole group.  
The thickness of gastric corpus mucosa was assessed in all animals at the 
end of the experiment. All animals treated with omeprazole showed gastric 
corpus mucosa hyperplasia, as expected, which was absent in untreated 






Figure 32. Effect of omeprazole-induced hypergastrinaemia on OE33-
GR tumour growth. A) Mean (+/- SEM) of groups of OE33-GR cell-only 
tumours (empty squares), and when co-injected with myofibroblasts (filled 
squares). Animals (n = 6 per group) treated with omeprazole in red, sham 
treated in black. Two animals exhibited accelerated tumour growth (0.6x106 
cancer cells with or without 241/6 NTMs 0.3x106. B & D: representative 
photomicrographs of one of the fast growing tumours. C & E: representative 






Figure 34: Omeprazole induces gastric mucosal hyperplasia in nude 
mice: Gastric mucosal thickness in nude mice (n = 6 per group) enrolled in 
the xenograft experiment with OE33-GR cells. A) mucosal thickness of 
omeprazole treated-mice shown in red bars and control animals in black bars. 
Statistical significance in t-test p<0.0001. B) representative photomicrographs 
of murine corpus mucosa of animals treated with omeprazole (right) and 
vehicle only (centre); scale bar = 200 µm.  
 
8.5 Discussion 
In this chapter I addressed the question of the role and fate of primary 
oesophageal myofibroblasts in xenografts and whether human myofibroblasts 
exert a systemic effect on tumour growth in xenografts. I therefore established 
a xenograft model with the use of primary human myofibroblasts and 
oesophageal cancer cell lines. 
Oesophageal cancers are the fastest raising malignancies in industrialised 
countries and advanced tumours are still associated with high-risk surgery 
and poor survival rates. Myofibroblasts have been shown to play an important 
role in the tumour microenvironment. The effect of myofibroblasts on tumour 
growth per se in immunosuppressed mice has been investigated previously 
for various carcinomas (oral squamous cell carcinoma (222), pancreas (223), 
breast cancer (224), stomach (97)), but the role of primary human 
myofibroblasts has not yet been studied to our knowledge.  
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We observed rapid early tumour formation after injection of xenografts 
containing myofibroblasts. This early tumour formation was only very mildly 
established or absent when cancer cells were injected alone. The early 
tumour results from a predominantly pauci-cellular oedema.  
Most studies document tumour measurements only 5 days after injection and 
seem to ignore early tumour formation. Very early tumour formation is likely to 
be an inflammatory process related, for example, to the release of histamine, 
cytokines and tumour necrosis factors. The main focus of the present study 
was on the role of the myofibroblasts within the first days when the injected 
cells are believed to integrate into the host tissue.  The complement system 
has been reported to play an important role in stromal cell activation (225). 
Bulla et al. observed a C1 upregulation two days after xenograft injection in 
stromal cells. When we injected myofibroblasts together with cancer cells we 
observed a complex tumour network as can be seen at the invasion front of 
oesophageal carcinomas in patients. It appears that the myofibroblasts form a 
niche which enables the cancer cells to thrive. The observations in vivo mirror 
observations of mixed cell cultures where myofibroblasts stand in contact with 
cancer cells and migrate through the expanding cancer cells. Dvorak 
commented on the importance of fibrin deposition in the generation of a 
desmoplastic stromal reaction (226). The histological picture in day 2 mixed 
tumours differs significantly from animals where cancer cells alone were 
injected. In the latter cancer cell embedding in the host tissue was delayed by 
more than two days.  
Additionally, xenografts which derive from combined myofibroblasts/cancer 
cell injections demonstrated an accelerated tumour growth. The grafting of 
CAMs, which can be regarded as activated myofibroblasts, accelerated 
tumour growth that was even more pronounced. Our findings are comparable 
to the results from Patel et al (227) on studies performed with primary 
squamous cell carcinomas of the skin. Patel et al. describe that for successful 
passaging of initial xenograft into a second recipient mouse, human stromal 
cells are required for successful xenograft formation.  
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Our studies on the fate of myofibroblasts co-injected together with OE21 and 
OE33 cancer cells into nude mice using fluorescently-labelled myofibroblasts 
and I-FISH revealed that all myofibroblasts primary cell lines tested disappear 
and are replaced by stromal cells of murine origin. Quante et al and 
Hutchinson et al have independently demonstrated that bone marrow derived 
stromal cells can migrate into tumours and differentiate into cancer 
associated myofibroblasts  (66, 228). Morton et al. demonstrated in an 
elegant humanised mouse model how bone marrow derived human cells 
become part of the stromal tumour component in xenografted head and neck 
cancers (229). A similar result was also demonstrated by Terai and his 
colleagues who identified ‘‘fibrocytes’’ in xenografted MKN45 cancers to 
contribute to tumour growth and fibrosis. Terai et al also found that tumours 
where fibrocytes were injected together with the cancer cells demonstrated a 
more pronounced αSMA expression in the stromal cells (68). This underlines 
the findings of Kumar et al where he demonstrated that myofibroblasts attract 
bone marrow derived stromal cells via chemerin (95). We have observed the 
presence of murine stroma cells in xenografts where myofibroblasts were 
injected together with cancer cells. We did not address the question of the 
origin of the murine stromal cells. The majority of stromal cells derive from the 
surrounding tissue as demonstrated by Arina et al. (230). 
Little is known about the fate of stromal cells in xenografts. Morton et al found 
persistence of human bone marrow derived stromal cells in his chimeric 
mouse model in late stage tumours (229). This contrasts with our finding 
where human myofibroblasts are not detectable in xenografts four weeks after 
injection. In the case of the humanised chimeric models the injection of 
progenitor stem cells provide an ‘unlimited’ source for cell renewal, whereas 
in our experimental setting where (presumably) terminally differentiated cells 
were injected the limiting factor could have resulted from apoptosis as 
observed in wound healing (231).  
Our findings also stand in accordance with observations by Liu and Hornsby 
who injected stress (bleomycin) induced premature senescent fibroblasts   
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together with MDA231 breast cancer cells into immune compromised SCID 
mice (224). They observed a disappearance of the grafted stromal cells two 
weeks upon injection together with the tumour cells. In colorectal cancer 
xenografts grafted stromal vascular cells have been described to disappear 
after three weeks (232). Duda and his co-workers addressed the question 
about the fate of transplanted stromal cells with the use of tumour stroma 
derived from GFP transgenic mice. After passaging the fluorofor-expressing 
stromal cells into non-fluorescent mice predominantly vascular labelled cells 
were detectable one month after transplantation whereas myofibroblastic cells 
had disappeared (233).  
Together the findings suggest that stromal cells play a pivotal role in the early 
embedding by niche formation in the xenograft setting. This might also 
explain why cancer cells are often difficult to grow whereas patient derived 
xenografts are very successfully transplantable and of great use for 
individualised anti cancer therapy (234). In PDX, human derived transplanted 
myofibroblasts persist in the transplanted tissue fragment and allow to gain 
deep insight on the cancer stroma interaction (235), however the stromal cells 
disappear after passaging (232). 
Liu and Hornsby showed that myofibroblasts induce cancer cell proliferation 
as long as the ratio of stress-induced premature senescenced fibroblasts to 
cancer cells was above 1 (224). Moreover, results from our group have 
demonstrated that conditioned media from myofibroblasts increased cancer 
cell proliferation (170). In oesophageal cancers fibroblast derived Wnt2 has 
been shown to activate cancer cell proliferation (236).  
Patients affected by cancer can demonstrate a variety of systemic 
manifestations anatomically distant from the primary tumour sites and 
malignancies can be regarded as a systemic diseases. Tumour cells can be 
detected in circulation as well as cellular particles such as extracellular 
vesicles, exosomes and microsomes and even free circulating nucleic acids 
(i.e. DNA and micro RNA) have been described. Little has been reported on 
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the role of the stromal cells on systemic effects. As mentioned above, CAMs 
secrete chemerin which can lead to homing of MSCs to the primary tumour 
site (95, 170).  In xenograft experiments, CAMs injected together with MKN45 
cells resulted in a suppressed growth of distant xenografts consisting of 
MKN45 cells only(97). In the present study, the injection of 467/1 CAMs 
together with OE21 cells led to an accelerated growth of contralateral OE21 
only indicator tumours. The presence of CAMs therefore may be a reason 
why resection of the primary tumours in the metastatic setting can extend the 
overall survival rate (237). Pre-treatment of NTM line 241/6 with DAC as 
described in the previous chapter accelerated the growth of mixed tumours, 
but did not affect the growth of indicator tumours.  
As part of the work on upper GI tumours we also asked whether the tumour 
stroma plays a role in gastrin-related Barrett’s adenocarcinoma propagation. 
In the past gastrin signalling through the CCK2 receptor has been shown to 
exert stimulatory effects on tumour growth (238). We observed an 
accelerated tumour growth in 1/3 of cases when myofibroblasts were admixed 
to xenografts with Barrett’s cancer cells expressing the CCK2 receptor 
(OE33GR) and these tumours were exposed to omeprazole-induced systemic 
hypergastrinaemia. The assessment of gastrin levels was attempted but 
failed for technical reasons. Gastric glandular hyperplasia which is a 
surrogate marker for trophic responses to prolonged hypergastrinaemia was 
documented in all omeprazole treated animals.  The influence of gastrin on 
tumour development has been found to include inhibition of gastric 
carcinogenesis (239), while blockade of the CCK-2 receptors inhibited gastric 
carcinoid tumour development (240). We expected to observe an accelerated 
tumour growth in the omeprazole treated group in xenografts consisting of 
NTM+OE33-GR. Against our expectations only two animal in the NTM+OE33-
GR group presented a rapid tumour growth. Omeprazole has been reported 
to inhibit tumour growth (241) and hypergastrinaemia itself has also been 
reported to decrease tumour growth (242). In all other grafted animals no 
substantial tumour growth was observed within three month. The low 
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penetrance of tumour growth in our hands might have been related to a 
relatively low number of cancer cells injected into these animals.  
The rapid growing tumours in the omeprazole treated NTM+OE33-GR group 
showed centrally solid cancer cell growth with an infiltrating growth pattern in 
the tumour periphery. This is in contrast to the other tumours in this 
experiment where a prominent intra- and peri-tumoural fibrosis was evident. 
On H&E stained slides there was no significant morphological difference after 
2.5 months between tumours in omeprazole treated animals and controls or 
tumours were myofibroblasts were co-injected. Clearly further experiments 




9 Oesophageal cancer associated myofibroblasts 
are epigenetically distinct 
9.1 Introduction 
Epigenetic regulation of gene expression has been documented in malignant 
cells and in cancer associated stromal cells (i.e. cancer associated fibroblasts 
or myofibroblasts in different cancers (109, 243). Little is known of epigenetic 
changes occurring in stromal cells in oesophageal cancer. We therefore 
compared seven pairs of CAMs and ATMs from oesophageal squamous cell 
carcinoma and adenocarcinoma patients using the Illumina450k methylation 
array. These findings were aligned with expression data of an Illumina HT 
expression array as well as a previously performed expression array in the 
laboratory.   
Amongst others, ADAM metallopeptidase with thrombospondin type 1 motif 
12 (ADAMTS12), paired-like homeodomain 2 (PITX2) and secreted frizzled-
like protein 2 (SFRP2) were identified as potentially interesting candidates for 
further investigations.  
ADAMTS12 is a metalloproteinase which has been shown to play an 
important role in tumour stroma remodelling (244, 245). SFRPs are negative 
regulators of the Wnt signalling pathway (246) and changes in their 
expression due to altered methylation have been associated with the 
adenoma-carcinoma progression (247). SFRP2 has also been shown to be 
differentially expressed in lung (108) and colon cancer associated stromal 
cells (244). PITX2 is a transcription factor and downstream effector of the 
Wnt/β-catenin signalling pathway (155, 157).  
As myofibroblasts influence the tumour microenvironment, amongst other 
mechanisms, through their secretion of proteases and signalling peptides, the 
effects of modulated ADAMTS12, PITX2 and SFRP2 expression in 
myofibroblasts was studied. Therefore ADAMTS12, PITX2 and SFRP2 
expression in myofibroblasts was modified by siRNA knock-down and 
plasmid overexpression. Whereas modulation of PITX2 and SFRP2 was 
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successful, only knock-down of ADAMTS12 was achieved and the target not 
further investigated. Effects of altered PITX2 and SFRP2 expression on 
myofibroblasts proliferation and migration as well effects via conditioned 
media on OE21 proliferation or on human umbilical vein cell network 
formation were studied. 
9.2 Objectives 
The specific objectives were: 
• To compare the DNA methylomes and transcriptomes of CAMs and 
ATMs with a view to identifying DNA methylation sites that determine 
mRNA transcription. 
• To select and validate candidates for further study where altered DNA 
methylation regulates protein expression in CAMs. 
• To determine whether the phenotype of cells with defined methylation 
patterns can be changed by overexpression/siRNA knock-down of target 
genes.  
 
9.3 Material and Methods 
Methylation array: DNA for an Illumina 450k methylation array was isolated as 
described (materials and methods 5.6.1) and the array run by an external 
service provider (HOLOGIC®; Manchester; UK). 
The methylation array was validated by pyrosequencing on CpG sites 
cg15482122, cg20043105, cg12967137, cg16458436, cg08318726, 
cg13071812, cg26620157, cg25469418, cg18229107, cg16803846 and 
cg14435644 as described (materials and methods 5.6.11, table 2). 
Expression modulation (overexpression and knock-down) was performed for 
ADAMTS12, PITX2 and SFRP2 overexpressing plasmids (see materials and 
methods 6.2.5 table 5) or knock-down siRNA for these targets.  
EdU incorporation assays (see materials and methods 5.2.6), migration 
assays in Boyden chambers (see materials and methods 5.2.4) and 
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branching morphogenesis assays (see materials and methods 5.2.12) were 
performed as described. 
9.4 Results 
9.4.1 Results of Illumina 450k methylation array  
A large number of the significantly differentially methylated CpG sites were 
not assigned to specific gene related loci (gene promoters, gene bodies or 
CpG islands) and were excluded from the analysis. In a paired comparison of 
significantly differentially methylated CpG sites in all seven CAMs and ATM 
(OeAC and OeSCC) a total of 4909 CpG sites were identified as at a cut-off of 
20 % CpG methylation difference between the two (figure 35). Relative 
hypomethylation of CAMs in relation to ATMs was more frequent, 3483 vs 
1426 (71 %); of these, 101 were located in promoter sites: 79 (78.2 %) in 
CAMs vs 22 in ATMs, and 79 located in gene bodies: 69 (80 %) in CAMs vs 
16 in ATMs; 39 were located in CpG islands: 19 (48.7 %) CAMs vs 20 in 
ATMs. When comparing the three pairs of adenocarcinoma CAMs with ATMs, 
5303 CpG sites showed significantly changed methylation. At all sites, CAMs 
were more frequently hypomethylated than ATMs, 4083 (77 %) in CAMs vs 
1120 in ATMs, of which 106 were located in promoter sites: 87 in CAMs 
(82.1 %) vs 19 in ATMs; 82 were located in gene bodies: 75 (91.5 %) in 
CAMs vs 7 in ATM; 27 were located in CpG islands: 17 (27 %) in CAMs vs 10 
in ATMs.  When comparing the four pairs of squamous cell CAMs, 16473 
CpG sites showed significantly different alteration in methylation with CAMs 
being frequently hypomethylated in relation to their matching ATM sites: 9000 
(54.6 %) vs 7473; of these 330 were located in promoter sites: 190 (57.6 %) 
in CAMs vs 140 in ATMs;  256 were located in gene bodies: 142 (55.5 %) in 
CAMs vs 114 in ATMs; 244 were located in CpG islands: 119 in CAMs 




Figure 35: Illumina450k methylation array dendrogram for CAMs vs 
ATMs. 2D heat plot of all CpG sites comparing all CAMs (SCC CAMs in red 
and AC CAMs in orange, bottom) vs all ATMs (SCC ATMs in dark green, AC 
ATMs in light green, bottom) note segregation of CAM and ATM signatures 
with a single exception (282/1). 
 
9.4.2 Validation of Illumina 450k methylation arrays 
Validation of the Illumina 450k methylation array data by pyrosequencing was 
performed at 12 different DNA sites and showed a 91.2 % overlap (52 out of 
57 pairs) of relative changes in methylation between CAMs and ATMs in the 
array compared with pyrosequencing. For illustration, three samples of 
individual pairs are shown in figure 36, and the net change of correlation for 





Figure 36: Validation of methylation array by pyrosequencing. Three 
examples of CpG sites on the array (cg25469418: TMEM51, cg22717014: 
PITX2, cg14435644: SFRP2). On the left side, values for three different CpG 
sites on the Illumina 450k methylation array in five pairs of CAM/ATM; on the 
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Figure 37: Summary of the validation of Illumina450k methylation array 
by pyrosequencing. Linear regression analysis of relative change in CpG 
methylation between CAMs and ATMs determined by pyrosequencing (Y-
axis) compared to methylation arrays (X-axis); black dotted line shows the 
line of equivalence. The overlap of change between results of the methylation 
array and pyrosequencing between paired CAM and ATM  (hypomethylated / 
hypermethylated / unchanged) in twelve different paired (number of pairs 
labelled on graph) are shown.  Overlapping results were obtained between 
the Illumina 450k methylation array and pyrosequencing in 12 pairs of 
samples and in 52 of 57 amplicons (91 %). Slope for matching 
pyrosequencing results Y = 1.176*X - 1.255, Pearson’s r=0.7426, statistical 
significance in correlation analysis p=0.0057. 
 
9.4.3 Target selection 
Three genes, ADAMTS12, PITX2 and SFRP2, showed a significant 
difference between CAMs and ATMs in CpG methylation in the Illumina450k 
and in a previously established expression array performed by the group 
(Varro et al., personal communication). Methylation maps for SCC and AC 
CAMs and ATMs for SFRP2 are shown in figure 38, and for PITX2 in figure 
39. Variance of expression in IlluminaHT expression array for SFRP2 and 
PITX2 are shown in figures 40 and 41 respectively. To further validate these 
targets for biological studies the success of knock-down of ADAMTS12, 
PITX2 and SFRP2 by siRNA in CAMs, or overexpression by plasmids 
























of all three genes by siRNA was successful in decreasing target expression 
by 90 %. Overexpression (over 10,000 fold) was successful for PITX2 and 
SFRP2, whereas an overexpression of ADAMTS12 by the plasmid construct 




Figure 38: CpG methylation of SFRP2 in CAMs and ATMs. Using data 
from the Illumina450k methylation array, the mean values of individual CpG 
site methylation (as percentage on y-axis) are shown for SFRP2 in SCC 
CAMs (red) and SCC ATMs (black)(A), and in AC CAMs and AC ATMs (B). 
Statistically significant altered methylation (p<0.05) at individual sites is 
marked with asterisk. X-axis represents distance in base pairs starting from 
the first CpG island allocated to the gene (cg04959480).  
 
 
Figure 39: CpG methylation of PITX2 in CAM and ATM (Illumina450k 
methylation array). Using data from the Illumina450k methylation array, the 
mean values of individual CpG site methylation (as percentage on y-axis) are 
shown for PITX2 in SCC CAMs (red) and SCC ATMs (black)(A), and in AC 
CAMs and AC ATMs (B). Statistically significant altered methylation (p<0.05) 
at individual sites is marked with asterisk. X-axis represents distance in base 






































































































































Figure 40: SFRP2 is upregulated in SCC CAMs. Illumina HT expression 
array signal intensity (y-axis) for SFRP2 in CAMs and ATMs (matched pairs 
connected by a line) in myofibroblasts from SCC patients (A) and AC patients 
(B). 
 
Figure 41: PITX2 expression does not vary between SCC or AC CAMs 
and ATMS. Illumina HT expression array signal intensity (y-axis) for SFRP2 
in CAMs and ATMs (matched pairs connected by a line) in myofibroblasts 







































































Figure 42: Overexpression and knock-down of putative targets. QPCR 
data showing change of expression (2^ΔΔCT) of ADAMTS12, PITX2 and 
SFRP2 upon plasmid overexpression (OE) or knock-down (KD) using three 
different siRNA constructs, in each case. 
 
 
9.4.4 Effects of SFRP2 on myofibroblast proliferation 
EdU incorporation by CAMs was reduced by knock-down of SFRP2 and 
increased in ATMs by overexpression although the results did not reach 

































Figure 43: Effect of SFRP2 expression on myofibroblast EdU 
incorporation. EdU incorporation (labelled cells as a percentage of total) 
after A) knock-down in CAMs by three different siRNA S1, S2, S3 (for 
average of all S1-3) and scrambled siRNA (SCR) or B) overexpression of 
SFRP2 or GFP controls in ATMs.  
 
9.4.5 Effects of SFRP2 on myofibroblast migration 
Knock-down of SFRP2 in CAMs reduced migration stimulated by IGF2. When 
SFRP2 was overexpressed in ATMs the increased migration in response to 
IGF2 was also decreased (figure 44).  
 
Figure 44: Effect of SFRP2 expression on myofibroblasts migration. 
Myofibroblast transwell migration in Boyden chamber assay after A) knock-
down of SFRP2 by siRNA S1, S2, S3 or scrambled siRNA (SCR) in CAMs 
(p<0.0001; one way ANOVA) or B) overexpression of SFRP2 in ATMs 
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9.4.6 Effects of myofibroblast-derived SFRP2 on Oe21 proliferation 
Conditioned medium from CAMs where SFRP2 was knocked down, or from 
ATMs where it was overexpressed, did not affect EdU incorporation in Oe21 
cancer cells (figure 45).  
 
Figure 45: Effects of conditioned medium from myofibroblasts with 
altered SFRP2 expression on OE21 proliferation. EdU incorporation 
(percentage labelled cells) in OE21 cells after 24 hour exposure to A) 
conditioned medium from CAMs where SFRP2 was knocked down by siRNA 
S1, S2, S3 or SCR controls or B) overexpressed in ATMs. 
 
9.4.7 Effects of myofibroblast-derived SFRP2 on endothelial network 
formation 
Conditioned medium from CAMs where SFRP2 was silenced decreased 
network formation of HUVEC cells in a branching morphogenesis assay 
(figure 46). Conversely overexpression of SFRP2 in ATMs  increased network 




















































Figure 46: Branching morphogenesis in HUVEC cells exposed to CM 
from SFRP2 expression supressed CAMs. Photomicrographs of HUVECs 
grown on Matrigel exposed to serum free medium on the left side and 
conditioned medium from myofibroblasts after knock-down of SFRP2 by 
transfection with siRNA on the right side. Panels A) and B) original images; 
Panels C) and D) overlayed after mesh analysis by the angiogenesis analyser 
plugin from imageJ. Segments in blue or green indicate contact with a 
junction (red). Master segments in yellow, networks in clear blue. Master 





Figure 47: Branching morphogenesis in HUVEC cells exposed to CM 
from SFRP2 overexpressing ATMs. Photomicrographs of HUVECs grown 
on Matrigel exposed to serum free medium on the left side and conditioned 
medium from SFRP2 overexpressing myofibroblasts on the right side. Panels 
A) and B) original images; Panels C) and D) overlayed after mesh analysis by 
the angiogenesis analyser plugin from imageJ. Segments in blue or green 
indicate contact with a junction (red). Master segments in yellow, networks in 







Figure 48: Effects of conditioned media from myofibroblasts with 
altered SFRP2 expression on angiogenesis. HUVEC total mesh area and 
master segment length (pixels) under exposure to conditioned medium from 
A) CAMs where SFRP2 was knocked down by siRNA S1 and SCR controls or 
B) overexpressed in ATMs. Statistical significance in paired t-tests. 
 
9.4.8 Effects of PITX2 on myofibroblast proliferation 
EdU incorporation in CAMs after transfection with siRNA against PITX2 
revealed a decreased incorporation with all three siRNAs tested. When PITX2 
was overexpressed in ATMs, the construct induced a loss of over 80 % of the 
transfected cells as compared to mock transfected controls. The remaining 
cells demonstrated a decreased EdU incorporation as compared to the 
controls (figure 49).  
 
Figure 49: Effects of PITX2 expression on myofibroblasts proliferation. 
EdU incorporation as percentage of total cells after A) knock-down of PITX2 
in CAMs by three different siRNA P1, P2, P3 and scrambled siRNA (SCR) 
(single value observation) or B) overexpression of PITX2 or GFP controls in 



















































































9.4.9 Effects of PITX2 on myofibroblast migration 
Knock-down of PITX2 by siRNA increased the basal migration of 
myofibroblasts in Boyden chamber transwell migration assays compared to 
controls. In response to stimulation by IGF2 there was smaller relative 
increase of the migration, although higher absolute migration, compared to 
the controls. PITX2 overexpressing cells did not show increased basal 
migration, and migration was decreased after IGF stimulation (figure 50). 
 
Figure 50: Effects of PITX2 expression on myofibroblasts migration. 
Myofibroblast transwell migration in Boyden chamber assay after A) knock-
down of PITX2 by siRNA P1 and P3 or scrambled siRNA in CAMs; statistical 
significance a) p=0.033 (unpaired t-test), b) n.s. (one-way ANOVA), c) 
p=0.0001 (one-way ANOVA) or B) overexpression of PITX2 in ATMs. 
Stimulation of migration by IGF2; p<0.0001 (unpaired t-test).  
 
9.4.10 Effects of myofibroblast-derived PITX2 on Oe21 proliferation 
When Oe21 cells were exposed to conditioned medium harvested from CAMs 
where PITX2 was silenced with siRNA no difference in EdU incorporation was 
observed as compared to controls. Conditioned medium from PITX2 
overexpressing ATMs only moderately increased EdU incorporation in Oe21 
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Figure 51: Effects of conditioned media from myofibroblasts with 
altered PITX2 expression on OE21 proliferation. EdU incorporation 
(percentage) in OE21 cells after 24 hour exposure to conditioned medium A) 
from CAMs where PITX2 as knocked down by siRNA P1, P2, P3 or 




9.4.11 Effects of myofibroblasts-derived PITX2 on endothelial network 
formation 
Conditioned medium harvested from CAMs where PITX2 was silenced with 
siRNA decreased network formation in branching angiogenesis assays using 
HUVEC cells. In contrast, network formation by HUVEC cells was increased 
following exposure to conditioned medium from PITX2 overexpressing ATMs 





















































Figure 52: Effects of conditioned media from myofibroblasts with 
altered PITX2 expression on angiogenesis. HUVEC master segment 
length (pixels) under exposure to A) conditioned medium from CAMs where 
PITX2 as knocked down by siRNA P3 and SCR controls (A:p=0.078 




The starting point for the work described in this chapter was  the previous 
findings in our group of differences between CAMs and ATMs with regard to 
their secretomes and miRNA transcriptomes. A wealth of evidence suggests 
that transcription is epigenetically regulated and so we first assessed whether 
global methylation differs between ATMs and CAMs. In this chapter the 
results are presented of a study investigating the difference in methylation 
between CAMs and ATMs at a more detailed level using methylation array 
technology. We found over five thousand significantly different methylated 
sites and correlated these with the available expression data. We investigated 
genes from three different protein families, i.e. a metalloproteinase 
(ADAMTS12), a homeobox gene (PITX2) and a secreted signalling protein 
(SFRP2) as potential candidates for DNA methylation regulated expression 
by combining the results of the Illumina450k methylation array together with 
previous expression array data available. We successfully overexpressed and 
supressed the expression of PITX2 and SFRP2, whereas over expression of 
ADAMTS12 was unsuccessful. The main findings are that SFRP2 is 











































corresponding ATMs and that SFRP2 is up-regulated in CAMs. Furthermore 
we found that overexpression of SFRP2 in ATM’s induced angiogenesis, 
whereas knock-down of SFRP2 by siRNA in CAMs decreased angiogenesis, 
suggesting that SFRP2 secretion by myofibroblasts regulates angiogenesis in 
the tumour microenvironment. 
The Wnt/β-catenin signalling pathway is a key element of carcinogenesis 
(248). SFRP family members have been attributed negative regulatory roles 
in the Wnt signalling cascade (249, 250). SFRP is downregulated in colorectal 
cancer by promoter hypermethylation which leads to an activation of Wnt/β-
catenin signalling (251); moreover, reintroduction of SFRP expression leads 
to suppression of the Wnt signalling cascade. Silencing of SFRP family 
proteins in tumour stroma through promoter hypermethylation has been 
described for SFRP1 in colorectal cancer (140) and NSCLC (252). Also in 
basaloid oesophageal carcinomas, a rare entity of squamous oesophageal 
carcinoma SFRP expression has been shown to be epigenetically regulated 
(148).  Moreover, altered expression of SFRP family members have been 
described in oesophageal adipocytes (253), although the authors did not 
investigate the mechanism of regulation.  The present results show, for the 
first time, that in stromal cells too SFRP family members are epigenetically 
regulated. With the use of methylation array technology and PCR based 
technology we show that SFRP2 is hypomethylated 1450-840bp upstream of 
exon1 in squamous oesophageal CAMs as compared to paired ATMs.   
In general, little is known on the role of stromal SFRP expression. The most 
interesting finding in our functional analyses was that myofibroblasts-derived 
SFRP2 affected angiogenesis in vitro: conditioned medium from SFRP2-
overexpressing myofibroblasts stimulated vascular network formation, 
whereas downregulation reduced network formation. SFRP family members 
are known pro-angiogenetic factors (254, 255). SFRP2 is a known inhibitor of 
the Wnt/β-catenin-signalling cascade and has been shown to promote 
neovascularisation in cancers (256). CAMs have previously been shown to 
exhibit angiogenic potential through VEGFα secretion (257, 258). Our findings 
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support the idea that CAMs also exert angiogenic effects by SFRP2 secretion 
and that this mechanism is epigenetically activated in CAMs.  
These data therefore raise the possibility that DNA methylation regulates 
expression of SFRP2 in myofibroblasts in oesophageal squamous cell 
carcinomas that is in turn associated with tumour outcome. Microvascular 
density in oesophageal squamous and adenocarcinomas has not been 
associated with tumour outcome (259), however high microvascular density 
was a negative predictive factor for neo-adjuvant radiotherapy response in 
primary oesophageal cancers (260). Whether SFRPs influence 
responsiveness towards radiation therapy remains to be elucidated. 
PITX2 is a transcription factor and regulator of the Wnt/β-catenin signalling 
cascade. Overexpression of PITX2 has been associated with increased 
transcription of most of the Wnt-related genes which is associated with cell 
proliferation and migration through a transcriptional activation directed at the 
Wnt2 and Wnt5a promoters (155). We observed a moderate decrease of 
CAM proliferation upon PITX2 knock-down by siRNA. This decrease in 
proliferation could be explained by a decrease of a constitutively activated 
Wnt/β-catenin signalling axis in CAMs and a decreased TGF β stimulus as 
described by Basu et al (261). The overexpression of PITX2 in ATMs also 
decreased proliferation of transfected myofibroblasts. These data have to be 
interpreted with caution as overexpression of PITX2 in our experiments was 
associated with a substantial cell loss. Our observation that conditioned 
medium from PITX2 overexpressing myofibroblasts leads to an increase of 
OE21 proliferation mirrors the results published by Basu et al where CM from 
transiently transfected cells induced transcription of CCND1 and c-MYC.  
Interestingly downregulation of PITX2 in CAMs was associated with an 
increased basal migration which contradicts findings on migration of PITX2 
knock-out myogenic cells in vivo (156) and findings by Basu et all where they 
show that PITX2 expression increases ovarian cancer motility by activation of 
TGF β pathway (261). Overexpression of PITX2 in myofibroblasts did, 
however, significantly affect cell migration. 
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CM from CAMs where PITX2 was knocked down suppressed angiogenesis, 
whereas CM from ATM where PITX2 was overexpressed increased 
angiogenesis. Currently there are no data available on the effect of PITX2 on 
angiogenesis and we can only hypothesise that a modulation of the Wnt/β-
catenin signalling pathway or other PITX2 regulated genes induce 
angiogenesis. Recently it was reported that regulation of Wnt through FOXO1 
significantly modulated vascularisation; thus downregulation of MYC by 
FOXO1 overexpression led to a reduction of endothelial sprouting whereas 
activation of MYC had the opposite effect (262). It is likely that PITX family 
members are direct regulators of angiogenesis through regulation of MYC.  
The main findings of this chapter are (a) that the DNA methylome of 
oesophageal CAMs is distinctively different from their matched ATMs. (b) 
That some of the functional differences between CAMs and ATMs are due to 
altered gene transcription regulated in turn by differential DNA methylation. 
(c) Two genes (PITX2 and SFRP2) whose products are implicated in Wnt/β-
catenin signalling display altered DNA methylation and transcription in 
oesophageal squamous cell carcinoma but not oesophageal adenocarcinoma 
related myofibroblasts. Modulation of PITX2 and SFRP2 expression by 
knock-down and overexpression in CAMs and ATMs not only alters their 
individual phenotype, but also leads to alterations of other cell types in the 
tumour microenvironment (i.e. OE21 squamous cell carcinoma cells and 
HUVEC cells). Collectively, these data enhance understanding of the role of 




10 Final discussion 
 
The work presented in this thesis shows that primary human myofibroblasts 
accelerate tumour growth in vitro and in vivo. (a) CAMs are shown to be 
epigenetically distinct from ATMs. (b) A novel model for epigenetic 
modification of stromal cells with the use of the DNMT inhibitor DAC is 
described. (c) Myofibroblasts are shown to play an important role in tumour 
niche formation in xenografts and (d) the tumour stroma in advanced 
xenografts is shown not to consist of transplanted stromal cells but rather is 
replaced by murine stromal cells. 
The field of cancer research has now moved from a tumour-centric view to a 
more nuanced understanding of the role of the tumour microenvironment (53, 
54). Thus it is now accepted that also non-cancerous cells in the tumour 
microenvironment are relevant players affecting tumour initiation, growth, 
metastasis and drug treatment.  
Our in vivo experiments show that primary human cancer derived 
myofibroblasts are main contributors to a tumourigenic microenvironment 
which enables cancer cells to seed and grow as postulated by Paget (10). 
This is a key finding and has to our knowledge not been shown by others in 
this form.  
It is well established that cancer cells activate stromal fibroblasts or bone 
marrow derived mesenchymal stromal cells mainly through TGFβ signalling to 
become activated myofibroblasts. Most of this evidence has been acquired 
from transgenic animal models or investigations on human derived FFPE 
tissue, but never directly from observations of primary human stromal cells in 
combination with cancer cells. Although efforts to mirror the in vivo situation 
including increasingly elaborate in vitro models such as 3-D cultures (174), 
chamber systems (263), spheroids (264), enteroids (265), or even in silico 
models (266) of the events occurring in the tumour microenvironment, 
nevertheless the fact is that xenograft models remain a pillar of cancer 
research. In particular, the multi-layered aspect of the tumour 
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microenvironment cannot be reproduced in all its complexity in vitro; 
moreover, systemic effects and metastatic spread of tumours inevitably 
requires research in entire organisms.  
The present findings enhance and extend what has been assumed from 
earlier work – namely that activated myofibroblasts in the tumour 
microenvironment are able to supply the necessary components which 
accelerate the host cells to form a complex microenvironment that replaces 
the human stromal cells and in the end accelerates tumour growth. This 
stands in line with current models on anticancer therapies which target the 
tumour stroma (267).  
Most xenograft studies described in the literature do not show xenograft data 
from the period immediately following tumour injection (229) (224) (268) (269) 
Thus, descriptions of tumour development in the first two days are mostly 
unreported, presumably because the initial swelling observed is interpreted as 
non-specific and related to inflammatory stimuli due to the injection. 
Furthermore effects related to tested substances are expected to occur at 
later time points. Our data confirm that myofibroblasts generate an 
environment hospitable for tumour cells to expand from the very beginning 
onwards. Already as early as two days after injection, murine non-
inflammatory cells invade between the injected human myofibroblasts and 
cancer cells which stands in line with a recent publication on the origin of 
tumour stroma cells (230). One month after xenografting human 
myofibroblasts were not detectable and all stromal cells were of murine 
provenance. This also stands in line with the role of niche formation prior to 
the development of metastases (270, 271). It is well established that cancer 
associated stromal cells promote cancer cell proliferation and mobility as well 
as angiogenesis and microvessel density within the tumours (59, 95, 272, 
273); these are associated with adverse outcome and drug resistance (274, 
275). In the setting of xenografts, the effects originating from myofibroblasts 
seem to occur within the first two days. Myofibroblasts give cancer cells a 
growth advantage and accordingly lead to an accelerated tumour growth. One 
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practical consequence is that co-injection of stromal cells might be a suitable 
option to promote growth of cancer cells which are normally difficult to grow 
as xenografts.  
The present data indicate that cancer associated myofibroblasts of the 
oesophagus are epigenetically distinct from matched adjacent tissue 
myofibroblasts. Genes encoding a transcription factor (PITX2) and a 
regulatory protein (SFRP2) both show altered methylation signatures and 
expression patterns between oesophageal cancer CAMs and ATMs and are 
both implicated in Wnt/β-catenin signalling. Moreover, the data show that 
upregulation of SFRP2 in myofibroblasts induces angiogenesis and 
supporting the hypothesis that epigenetic modification regulates myofibroblast 
derived SFRP2 expression which may play an important role in tumour 
neovascularisation.  
CAMs are phenotypically distinct from ATMs which has been demonstrated 
for myofibroblasts in lung (82), stomach (60), colon (85), (83) and others. 
Whereas mutations, translocations and chromosomal instability are a 
hallmark of malignant transformation in cancer cells, such alterations were 
reported to occur rarely in CAFs  (276). However, it is important to stress that 
cancer cells undergoing EMT might be identified as mutation-bearing stromal 
cells and thus account for a portion of the reported mutations occurring in 
cancer associated stromal cells (277). 
Myofibroblasts have been shown to interfere with anticancer therapy by 
different groups (278, 279). Growth factors have been identified as a key 
player compromising the anticancer effect of targeted drugs such as EGFR 
and HER2 tyrosine kinase inhibitors and RAF GTPase inhibitors. I have 
shown in the previous chapters that chemical epigenetic modification of 
stromal cells with DAC lead to an accelerated tumour growth, suggestive that 
if stromal cells can be modified to promote tumour growth there should also 
be a way to interfere with their tumour promoting ability.  
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These findings underline the important role of the tumour microenvironment 
and myofibroblasts in particular. It also suggests that more effort in 
understanding the tumour stroma will be needed in order to find new anti 
cancer therapies.  
We hypothesised that the persistence of phenotypic changes observed in 
CAMs are epigenetically defined. Gonda et al (73) as well as others (85, 108, 
280) have shown previously that CAMs demonstrate a modified DNA 
methylation pattern as compared to their normal counterparts. Our finding of a 
global change in DNA methylation is also compatible with a previous report 
that CAFs show a loss of global DNA methylation and only focal gain of DNA 
methylation in a chemically induced gastric cancer model (109). In describing 
epigenetic differences between CAMs and ATMs the data therefore contribute 
to the rather sparse knowledge on epigenetic regulation of cancer associated 
stromal cells (281).  
The understanding of epigenetic regulatory processes in the stromal tumour 
microenvironment has become important as drugs influencing epigenetic 
processes such as the DNA methyl transferase inhibitors 5-AzaC and 5-
AzaDC and the histone-deacetylase inhibitors vorinostat and romidepsine 
have become available for anticancer treatment. Also miRNAs which are 
regarded as epigenetic regulators are being tested for anticancer treatment 
(282). The data indicate specific on-target results that appear promising, but 
even so off-target effects might lead to unwanted effects such as accelerated 
tumour growth as suggested by the present findings. The work in this thesis 
suggests that it would be appropriate to be cautious in extending the use of 
drugs in this class. One limitation of in vitro assays with regard to 
epigenomics is that cells adapt to different environments for example when 
growing in different organs or when cultured on plastic which may itself 
induce altered DNA methylation patterns (283). Using low passage cells in 
our experiments and strictly standardised culture conditions we attempted 
to minimise artificial differences in our results. The data obtained from our 
paired analysis between CAM with ATM using the Illumina Infinium 
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HumanMethylation450 (450K) BeadChip array showed that significant 
epigenetic differences between CAMs and ATMs persist even after few 
passages on plastic. However, we cannot exclude that de novo epigenetic 
changes occurred obscuring changes present before culture in vitro. In paired 
analyses altered DNA methylation between CAMs and ATMs were compared,  
and in unpaired analyses CAMs, ATMs and NTMs were compared. The data 
generated by the unpaired analysis did not prove to be of statistical 
significance. This was likely related to the relative low cohort size and the 
high variability between individual patients. One disadvantage of the array 
might be that it has been designed for use on tumour cell lines and only 
detects predefined methylation sites within a selected range within the 
genome, thus potentially over-representing these regions and under-
representing others. Next-generation methylation sequencing (284) or other 
newer techniques (285) could now be used, however, these methods are 
more expensive and the data analysis is more demanding which precluded 
their use in the present study. 
In order to investigate the biological relevance gained by the methylation 
array, we matched the results with pre-existing data on gene expression in 
these cells. Functional analysis of PITX2 and SFRP2, both of which are 
involved in the Wnt/β-catenin signalling pathway showed significantly altered 
DNA methylation in the Illumina 450k methylation array and a significantly 
altered gene expression in an expression array (personal communication Prof 
Varro). The possibility of epigenetic regulation of PITX2 and SFRP2 has not 
been shown in cancer associated stromal cells before.  
TGF-β signalling is a key player in OESCC with dual signalling effects. In 
early tumour stages TGF-β signalling appears to antagonise tumour growth. 
Low expression levels of TGF-β were described to be associated with poor 
tumour differentiation and more advanced tumour stage at the time point of 
diagnosis (286-288). Contrary to this, in advanced tumour stages high levels 
of TGF-β were associated with more aggressive behaviour, presumably at 
least in part through the transforming effect of TGF-β on cancer associated 
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stromal cells, which in turn promotes tumour progression and angiogenesis 
(59, 95). TGF-β1 in fibroblasts leads to migration and invasion of 
oesophageal squamous cell cancer (289). Furthermore in both OEAC and 
OESCC TGF-β signalling has been shown to be associated with advanced 
tumour stages (289, 290).  
CAFs secrete Wnt2 which also leads to cancer cell proliferation (236). The 
authors have also raised the question of the role of Wnt2 in EMT. They have 
shown that CAFs with high expression levels of Wnt2 are associated with 
authentic CAF phenotypes which I would argue is better described as a 
CAMs. I found that SFRP2, a WNT/β-catenin signal competitor, exhibits a 
relative loss of DNA methylation and is up-regulated in SCC CAMs. In order 
to assess whether altered expression of SFRP2 affects the WNT/β-catenin 
signal cascade, phospho β-catenin expression levels or cyclin-D1 as 
surrogate markers of WNT/β-catenin pathway activation could have been 
assessed. Surprisingly, knock-down of SFRP2 lead to a decrease in 
myofibroblast proliferation whereas upregulation of SFRP2 increased 
proliferation. A lack of negative regulators of the WNT signalling pathway 
would lead to a decreased proliferation and vice versa. Fibroblast-derived 
Wnt has been shown to be involved in activation of the WNT/β-catenin 
pathway in mammary glands and tumours (291, 292), pancreatic 
adenocarcinoma (293), non-melanotic skin tumours (294), malignant 
melanoma (154), gastric adenocarcinoma (87) and OESCC.  The present 
observation showed the contrary. This raises the possibility that SFRP2 has a 
pro-mitotic effect in myofibroblasts, independent of the classical WNT 
signalling pathway. Knock-down and overexpression in myofibroblasts also 
lead to decreased myofibroblast migration. The effect of knock-down of 
SFRP2 on myofibroblasts could be explained in relation to canonical WNT 
signalling. In SFRP2 overexpressing cells however, competition with frizzled 
for the frizzled receptor might underlie the decrease in cell migration. Further 
experiments will be required to sustain this hypothesis.  
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CAFs play an important role in angiogenesis through VEGF signalling (295). 
In colorectal cancers, myofibroblasts and microvascular density are positively 
correlated with more aggressive tumour growth (296). This is of interest in the 
context of our observation that conditioned medium derived from cells where 
SFRP2 was knocked down inhibited vascular network formation, whereas 
conditioned medium from SFRP2 overexpressing myofibroblasts lead to an 
increase of vascular network formation. These findings are compatible with 
the published literature on the effects of other SFRP family members and 
their pro-angiogenic effects (154, 256). It appears that myofibroblasts which 
have undergone epigenetic modification might constitutively overexpress 
SFRP2 and thus contribute to angiogenesis in cancers.   
We found that PITX2, a transcription factor which plays an important role in 
embryogenesis and is a downstream effector of the Wnt/β-catenin signalling 
was hypermethylated in squamous cell carcinoma derived CAMs. A 
significant difference at the transcription level however was not detected. 
Nevertheless when we modified PITX2 expression in myofibroblasts, we 
found statistically significant effects on myofibroblasts proliferation, migration 
and angiogenesis. These data show that the downstream target of the Wnt/β-
catenin signalling directly interferes with cells involved in the tumour 
microenvironment. An experiment which could be performed in order to prove 
this hypothesis would be the assessment of PITX2 expression upon 
activation of the Wnt/β-catenin pathway.  
The findings regarding modulation and targeting of the WNT signalling 
pathway underline the important role of myofibroblasts and WNT/β-catenin 
signalling in the tumour microenvironment. It is now important for a general 
understanding of tumour biology to determine how non-malignant stromal 
cells are epigenetically modified in ways that promote angiogenesis.  
Finally, a novel model is described for epigenetic modification of cancer 
stroma cells: namely epigenetic modification of myofibroblasts using the 
DNMT inhibitor DAC. Epigenetic modification of myofibroblasts in vitro 
modifies cancer growth in vivo. We hypothesise that chemically-induced DNA 
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methylation leads to an activation of normally silenced genes leading to a 
biologically more active cell. Thus myofibroblasts treated with DAC over three 
days showed a mild decrease in global DNA methylation; a short treatment 
period with DAC also leads to persistent biological changes. In order to better 
understand the effects of DAC one could assess DNA methylation using array 
technology. DAC treatment affects mainly genes located in open nuclear 
euchromatin conformation where DNMT1 is active and leads to mild but 
persistent loss of methylation and minimally altered transcription in stromal 
cells (297). DAC has also been described to induce point mutations and 
genome rearrangements (114). DNMTs are highly expressed in proliferating 
cells and DAC is therefore likely to exert a stronger effect than in quiescent 
cells or cells with relatively low proliferation rates such as activated cancer 
associated stromal cells. A cell type specific, but otherwise random effect 
would be expected to occur when low passage myofibroblasts are treated 
with DAC. DAC is a Food and Drug Administration (FDA) approved cytosine 
analogue for the treatment of chronic myelomonocytic leukaemia and 
myelodysplastic syndromes. A recent in vivo study demonstrated anti-
proliferative effects of DAC on pulmonary myofibroblasts which show features 
of CAMs (298). Orskov and his colleagues observed in patients with 
myelodysplastic syndromes that DAC treatment leads to a hypomethylation 
and overexpression of PD-1 in CD8+ tumour T-cells which might lead to 
immunogenic exhaustion of the anti tumour immune response (299). Little is 
known on other effects of this agent on other stromal cells except for growth 
suppression as observed here. Importantly, though, persistent changes in 
myofibroblasts treated with DAC were found with respect to accelerated 
migration, contractility and invasion. Moreover, when DAC treated 
myofibroblasts were injected together with oesophageal cancer cells in nude 
mice, there was accelerated tumour growth. The model of epigenetic 
targeting of stromal cells in vitro and then the study of their influence on 
tumour growth in vivo is novel. It allows the investigation of epigenetic 
modification in stromal cells on tumour growth as compared to systemic drug 
application which would target all cells in the tumour microenvironment. DAC 
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has only recently been approved by the FDA and little is known of its long 
term effects. Our data and those of others would suggest that DAC can 
potentially transform myofibroblasts into activated myofibroblasts that support 
tumour growth. Importantly for the future, recent publications show that 
targeted modification of epigenetic signatures is possible (300, 301) and this 




11  Prospects 
 
Cancer epigenetics are of dual interest. First they may explain pathological 
mechanisms of disease the understanding of which may lead to new 
discoveries (with the ultimate aim of improved treatment options and better 
patient outcome). Therapies interfering with epigenetic mechanisms have 
been recently introduced in anticancer therapy. Stromal cells as shown in this 
work and by others undergo epigenetic modifications that can lead to tumour 
initiation, propagation and metastasis. Understanding the causes of this 
epigenetic phenotype switch could lead to new targets for treatment.  
Secondly, this work may facilitate the more successful prevention of cancer 
related death through tumour detection at an early or pre-invasive stage. In 
recent years sampling of cell-free circulating DNA has become a 
diagnostic minimally invasive tool for prenatal diagnostics (302) and detection 
of early tumour relapse (303). Advances in technology that allow detection of 
low levels of circulating nucleic acids could be applied not only to detect 
tumour derived circulating DNA but also inflammatory or stromal cell derived 
DNA methylation signatures. Fragments of the entire human genome have 
also been detected in extracellular vesicles such as exosomes. Exosomes 
can be isolated from blood but also from less invasively accessible body 
fluids such as saliva and urine. It remains to be elucidated whether 
extracellular vesicles carry methylated DNA and whether such is easily 




AD anno Domini 
AGS Gastric cancer cell line 
ATM adjacent tissue myofibroblast 
BC before Christ 
BM-MSC bone marrow derived MSC 
CAM cancer associated myofibroblast 
CAS cancer associated stromal cells  
CCK cholecystokinin receptor  
CM conditioned medium 
DAC 5’Aza-3’deoxy cytosine 
DAPI 4′,6-Diamidin-2-phenylindol 
DNA deoxyribonucleic acid 
DNMT DNA methyl transferase 
EdU 5-ethynyl-2’-deoxyuridine  
EMT epithelial to mesenchymal transition 
FDA Food and Drug Administration  
FFPE formalin-fixed and paraffin embedded  
HGF Hepatocyte growth factor 
HUVEC human umbilical vein endothelial cell 
IARC International Agency for Research on Cancer  
IGF Insulin like growth factor 
LINE long interspersed transposable elements 
miR micro RNA 
MKN45 Gastric cancer cell line 
MM myofibroblast medium 
MMP matrix metalloproteinase 
MSC mesenchymal stem cells  
NSCLC non-small cell lung cancer  
NTM normal tissue myofibroblasts 
OEAC adenocarcinoma of the oesophagus 
OESCC squamous cell carcinoma of the oesophagus 
PDAC pancreatic ductal adenocarcinoma  
PDGF platelet-derived growth factor 
PITX paired like homeodomain  
RNA ribonucleic acid 
SCID severe combined immunodeficiency 
SCR scrambled 
SFM serum free medium 
SFRP secreted frizzled like protein  
siRNA small interfering RNA 
SMA smooth muscle actin 
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TGF transforming growth factor-b 
TIMP tissue inhibitor of metalloproteinase 
VEGF vascular endothelial growth factor 
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